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Abstract
In this paper, we build a new, simple, and interpretable mathematical model to describe the human
glucose-insulin system. Our ultimate goal is the robust control of the blood glucose (BG) level of
individuals to a desired healthy range, by means of adjusting the amount of nutrition and/or external
insulin appropriately. By constructing a simple yet flexible model class, with interpretable parameters,
this general model can be specialized to work in different settings, such as type 2 diabetes mellitus
(T2DM) and intensive care unit (ICU); different choices of appropriate model functions describing
uptake of nutrition and removal of glucose differentiate between the models. In addition to data-
driven decision-making and control, we believe the model is also useful for the basic quantification
of endocrine physiology. In both cases, the available data is sparse and collected in clinical settings,
major factors that have constrained our model choice to the simple form adopted.
The model has the form of a linear stochastic differential equation (SDE) to describe the evolution
of the BG level. The model includes a term quantifying glucose removal from the bloodstream through
the regulation system of the human body, and another two terms representing the effect of nutrition
and externally delivered insulin. The stochastic fluctuations encapsulate model error necessitated
by the simple model form and enable flexible incorporation of data. The parameters entering the
equation must be learned in a patient-specific fashion, leading to personalized models. We present
numerical results on patient-specific parameter estimation and future BG level forecasting in T2DM
and ICU settings. The resulting model leads to the prediction of the BG level as an expected value
accompanied by a band around this value which accounts for uncertainties in the prediction. Such
predictions, then, have the potential for use as part of control systems which are robust to model
imperfections and noisy data. Finally, a comparison of the predictive capability of the model with
two different models specifically built for T2DM and ICU contexts is also performed.
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1 Introduction
1.1 Background
Broadly speaking mathematical models of human physiology may serve one of two purposes: elucida-
tion of the detailed mechanisms which comprise the complex systems underlying observed physiology;
or prediction of outcomes from the complex system, for the purposes of medical intervention to ame-
liorate undesirable outcomes. In principle these two objectives interact: a model which explains the
detailed mechanisms, if physiologically accurate and compatible with observed data, will of course be
good for prediction. However, in many complex human physiological systems, basic understanding
of the mechanisms involved is still developing. It is arguably the case that simple, interpretable,
models which are trained on observed data may suffice for the purpose of prediction and control,
in situations where the detailed underlying physiological mechanisms are not yet fully understood.
Additionally, human physiological data are often sparse, implying a limited capacity for resolving
high-fidelity physiological details and unique physiological inference. The human glucose-insulin sys-
tem provides an important example of a system where these issues come in to play because in most
settings, insulin—representing two of three dominant state variables—is never measured. Moreover,
depending on the purpose of the study and the structure and size of the available data, one needs
to decide the required level of model fidelity, [43]. Here, because we aim to resolve the mean and
variance of glucose dynamics, we ignore higher-fidelity physiology and build a lower-fidelity model in
a way that it includes common, clinically-relevant inputs. The objective of this paper is to introduce
a simple modeling framework for the human glucose-insulin system, which is interpretable, can be
trained on and largely limited to observed data and then has predictive capability, in a predictive test
data sense.
The model developed here is, in some sense, a radical departure from the norm. This is because
it proposes a closed model for blood glucose dynamics; meaning, the model includes parameters and
states limited to those either directly related to, or directly inferable from, commonly available data,
rather than the model including a full set of features believed to drive the system. The model treats
all unmeasured states that interact with blood glucose as either representable by inferred parameters
or as noise; in particular insulin levels are modeled through parametric dependence, which can be
modified to incorporate measured insulin delivery, whilst noise in the model allows for imprecision
arising from this simple approach. In this way, the primary hypothesis of this paper is to investigate
if a glycemic model, which does not include equations describing the evolution of interstitial and
plasma insulin levels in the body, can be used to represent and accurately forecast blood glucose while
retaining some physiological fidelity. The motivation for this formulation is built on both inference
and the scientific process. In general, lacking measurements for quantities related to dominant states
in the system, such as insulin, causes identifiability failure and hence instability in the inference. To
avoid this situation we represent insulin implicitly through parametric dependence within the equation
for glucose, with noise introduced to allow for inadequacies in this representation, instead of modeling
it explicitly via a state. Our results demonstrate that this approach is viable, as our model is able
to forecast glucose, by many metrics, as well or better than many accepted models which explicitly
model insulin.
In terms of flexibility and interpretability of inference, there is a trade-off between data assimilation
(DA) and machine learning (ML) approaches. In ML, we project data onto a complex, highly flexible
function space. However, the resulting algorithms often fail to be directly interpretable, limiting their
potential for use, and creating the possibility of unwanted and unexplainable effects. On the other
hand, in DA, we project data onto a model that is usually interpretable and this may be used to
design away unwanted and unexplainable effects. Our approach combines the data-driven nature, and
flexibility, of ML algorithms, whilst retaining some the interpretability, and benefits that stem from
it, that arise from DA.
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1.2 Literature Review
Depending on their particular purposes, researchers have developed various mathematical models
ranging from extremely simple to extremely complex to describe glucose metabolism in humans. Some
of these models are developed to describe a very specific system, for example, a particular biological
function of the pancreas [13, 34, 77], whereas others have been developed to predict hypoglycemia
[31, 61, 78], glucose control [11, 14, 24, 30, 70, 89, 91], or disease pathogenesis [32, 35, 36]. Some
of these are continuous-time models in the form of ordinary differential equations (ODEs) whilst
others use ML: in [13, 34, 77], the authors develop system of ODEs to model the phenomenon they
investigate while efforts directed at inference tasks such as predicting hypoglycemia, ML approaches
are more common. For example, to predict hypoglycemia, in [78], various classification methods, such
as random forest, support vector machine, k-nearest neighbors, are used. For the same purpose, in
[61] a simple model, consisting of a logistic function, based on the mean and standard deviation of BG
measurements, is developed, and in [31], a linear mixed effects model is used. In [88], an ML approach
is used to investigate the variability in postprandial BG levels to identical meals based on several
covariates such as blood parameters, dietary habits, and gut microbiota over a course of one week
time period for 800 individuals. With this method, the authors successfully predicted postprandial
blood glucose levels in a personalized manner and estimated personalized diets that could reduce the
postprandial blood glucose for these patients. Moreover, another class of ML models that are used for
analysis and prediction are the ARIMA (auto-regressive integrated moving average) models. In [59],
authors use an ARMAX model, which consists of an ARMA (auto-regressive moving average) model
combined with exogenous input model to analyze the data collected from T2DM patients. In [87], an
ARIMA model is used for forecasting BG levels, whereas in [60] a SARIMA (seasonal ARIMA) model
is used for the same purpose. On the other hand, for glucose control, a wide range of approaches are
used, such as systems of ODEs [11], combination of systems of ODEs and partial differential equations
(PDEs) [30], stochastic differential equations (SDEs) [89], and various network models [14, 91]. There
is also research to understand how T2DM patients and their health care providers reason about self-
collected data, how this type of data should be used to make accurate future BG level forecasting,
and what kind of strategies should be designed to maximize the usefulness of self-monitored data,
[57, 58]. In [23], a mobile application is developed for post-meal BG level forecasting with self-tracked
data. It is also tested on two populations; one consisting of individuals who are educated about
T2DM and familiar with mobile applications whereas the other consisting of individuals with low-
literacy and limited mobile app usage. Both population find the mobile app useful in managing their
disease. Another study investigating the reasoning mechanism of self-management strategies of T2DM
patients, which is reported in [22], shows the importance of effective visualizations in self-management
of T2DM. On the other hand, in [6], a DA framework is used for future BG level forecasting based on
self-collected data. The results obtained with the DA approach is compared with other approaches
such as Gaussian process model regression and with the prediction of expert diabetes educators. In
another work, [7], the DA framework was developed as a computational method, which combines ML
and mechanistic modeling to forecast future BG levels and to infer T2DM phenotypes. On the other
hand, in [33], a two compartmental relatively simple ODE model is used to analyze continuous glucose
measurement (CGM) data collected from T2DM patients to investigate possible improvements that
could be achieved with this type of data in the T2DM setting.
One of the earliest quantitative models was Bergman’s Minimal model [12]. This ODE model was
developed with the purpose of estimating insulin sensitivity in the intravenous glucose-tolerance test
(IVGTT) setting. Another widely-known ODE model was developed by Sturis et al. [77] with the
aim of elucidating the cause of the ultradian (long-period) oscillations of insulin and glucose. The
concluding hypothesis of the Sturis et al. [77] paper was that production of glycemic oscillations
required a model with three states beyond those described in the minimal model, interstitial insulin,
plasma insulin, and a delayed effect of the liver’s release of glucose. There are alternative hypotheses
for sources of ultradian oscillations due to other factors, e.g., [55], but in all cases a full description
of the ultradian oscillations and their careful validation with data remains an open question. One
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important theme in all of the papers that address ultradian oscillations points to a mathematical
feature that does seem to be required to produce ultradian glycemic oscillations: a delayed response
in glucose use and production. For example, routine numerical bifurcation analysis of the Sturis et
al. [77] model reveals that oscillatory dynamics appear via a—presumably Hopf—bifurcation due
to variation in parameters that control the time-delay governing hepatic glucose production. This
important observation led to the introduction of delay differential equations (DDEs) to model the
long-period oscillations of insulin and glucose. Others have developed models driven more strongly
by clinically-minded motivations. In [35], authors use a mathematical model to understand why it is
easier to prevent type 2 diabetes mellitus (T2DM) than to cure it; the model is based on a negative
feedback mechanism within a system of nonlinear ODEs, as an update to the pioneering model [80],
to describe β-cell mass, glucose, and insulin dynamics. Because they describe a specific aspect of
the system, these models are relatively simple and easy to interpret. There are models, on the
other hand, that aim to describe more complicated systems, with multiple and multi-scale interacting
components, such as the events that occur during oral glucose ingestion [21, 50]. These models are
comprised of a large number of ODEs or DDEs with many model parameters. Such models, which
describe events in a very detailed manner, are typically used to understand the physiological network
that results in the emergent behavior of the system. There are also machine learning models that could
be used for the same purposes. Time series analysis could be used to identify and exploit systemic
patterns in the data, and these patterns used to provide models for forecasting. In [1, 8] information-
theoretic methods were developed to understand and model phenotypic [4, 5] and health care process
(measurement process driven) [42, 44] differences observable from clinically collected glucose data.
These efforts led to [72] where a nonlinear computational model was used to estimate unmeasured
variables and unknown model parameters based on sparse measurement data for glycemic management
in ICU context. More directed at autoregressive modeling, in [16], using autocorrelation analysis of
continuous BG data, it is shown that future BG levels can be predicted by using recent time-history
of the glucose. Following this result, simple autoregressive modeling is used for forecasting, based
on continuous BG data collected from either type 1 or type 2 diabetic individuals, in [28, 74]. On
the other hand, in [45], linear regression model is used to examine the roles of insulin-dependent and
insulin-independent factors in glucose tolerance based on data collected during IVGTT.
The models cited in the previous paragraph are often developed in order to understand disease
pathogenesis, e.g., of T2DM, where the system generally changes much more slowly than state variables
evolve in time. In settings where the system evolves very quickly, e.g., in the intensive care unit
(ICU) setting, a number of additional hurdles appear for using the resulting computational models
for glycemic prediction and control. These include the wide variation in clinical response within and
between patients, and resultant concerns about safety issues. In [90], a model consisting of fractional
polynomials and interaction terms is used with a linear regression approach to determine the initial
insulin dose setting. In [82] Bergman’s Minimal Model is modified so that it applies beyond the initial
goal of explaining IVGTTs, and is instead applicable in the ICU setting. In this context it is referred
to as the ICU Minimal Model (ICU-MM). In [52], a control mechanism framework is developed that
uses two compartment glucose-insulin model accounting for time-varying parameters.
There is also a large body of research developed for similar purposes in type 1 diabetes mellitus
(T1DM) context, often under the umbrella of artificial pancreas/beta-cell research. Researchers have
long recognized the importance of efficient mathematical algorithm describing the glucose-insulin reg-
ulation, [17, 18, 20, 63, 64]. Indeed, in [17] and [63], mathematical model is explicitly counted as
one of the main components of artificial pancreas development. In all these works and many oth-
ers, [26, 27, 49, 79], that are focused on closed-loop-control of BG levels of T1DM patients, the
amount of insulin to be infused via a pump is decided based on mainly the CGM. Hence, the math-
ematical models mostly describe the glucose-insulin regulation without incorporating any nutrition
information. However, since nutrition is one of the main drivers of the BG level, developing models
accounting for nutrition factor and using these models within the human-in-the-loop control systems
for tight glycemic management in T1DM setting may have the potential to advance current glycemic
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management results and reduce the possibility of diabetes-related complications.
In all of the models discussed above, parameters enter and play an important role in making
predictions with the model, yet may be difficult to determine, as they are not directly measurable;
furthermore, their values will vary from one patient to another. There are two overarching approaches
to learning about parameters: optimization in which a model-data mismatch is minimized to deter-
mine parameters [25]; and the Bayesian approach [46] in which the distribution on the parameters,
given the data and given the assumed (noisy) model-data framework, is computed. Generally speak-
ing the Bayesian approach provides more information as it gives not only parameter estimates, but
uncertainties; this can be very useful in biomedical prediction as it may be used to predict, and hence
avoid, rare events with extreme consequences. These advantages are not free, the Bayesian approach
is typically more costly as it requires determining an entire distribution and not just a point. The
two are linked through the negative logarithm of the posterior distribution on the parameters, which
is a penalized model-data mismatch functional. In [82] parameter estimation is performed based on
surgical ICU data using a standard least-squares approach. In [39], building on an adaptive modeling
approach introduced in [82], the authors use the ICU-MM to predict BG levels of patients over a
moving time interval that starts right after the interval used for parameter estimation, employing a
nonlinear least-squares approach. In [10], the authors employ hybrid Newton observer design to pre-
dict BG levels of ICU patients within the framework of the ICU-MM; this is a method introduced in
[15] to obtain numerical solution of a system of nonlinear ODEs through simulation by using Newton’s
method and eliminating the dependence on the exact discrete-time model when this exact model is not
known analytically. Another approach developed in [40], the authors construct a mechanistic model
consisting of five sub-models describing glucose regulation in critical care. They adopt a Bayesian
approach in which the prior (regularizing) distribution is formed based on the both prior expert
knowledge and routinely collected ICU data. By this approach, time-invariant model parameters, as
well as a time-varying model parameter which represents the temporal variation in insulin sensitivity,
are estimated. Another mathematical model consisting of ODEs is developed in [86] in which, with
the exception of the time-varying insulin sensitivity parameter, all the model parameters are fixed at
reasonable values known a priori. Then, the insulin sensitivity parameter is estimated online with
a least-squares approach and used to compute future insulin input by minimizing a quadratic cost
function to control future BG levels.
There are also models that are specifically developed or used to control blood glucose levels of
ICU patients in a healthy range. In [67] the authors combine the intensive control insulin-nutrition-
glucose (ICING) model, introduced in [53] with a subcutaneous insulin delivery model for automated
insulin delivery system. In [48], in addition to the models used in [67], the authors add another model
representing the suppression of endogeneous glucose production by insulin, [71], again for purposes
of controlling BG levels of critical care patients. Similarly, in [47], the ICING model is used with
another model respresenting subcutaneous insulin dynamics, [84], in a linear zone model-predictive
control framework. Nonlinear models representing glucose-insulin dynamics are also of interest and
using these models for control purposes requires some modification in the computational methodology.
In [38], a general nonlinear model-predictive control (NMPC) schema is developed to be used for
control of systems governed by nonlinear dynamics. The problem of BG control in ICU is used as an
example to show the effectiveness of this NMPC approach in [38]. On the other hand, it is known
that the glycemic control in the ICU is fundamentally different than the glycemic control in diabetes,
as an ICU patient could experience an hyperglycemic episode without being diabetic. This situation
is caused by the body’s stress response rather than diabetes. Therefore, it could provide valuable
knowledge to understand the pancreatic response of ICU patients. For this purpose, in [65], the
authors construct an algorithm to assess the pancreatic response of critical care patients. They also
show the requirement of incorporating this system in BG control frameworks in in ICU settings. None
of these constructions have been shown to work robustly for data collected in an ICU, and appear to
require continuous glucose monitors (CGM) and/or insulin measurements to function propery; CGMs
are not common and insulin is never measured in ICU settings, posing a substantial barrier to use.
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An alternative, but related, approach to prediction is to consider BG levels as discrete time series
data and use models such as autoregressive integrated moving average (ARIMA) for prediction. In
[87], the authors use an ARIMA model to predict blood glucose levels and hypoglycemia. For similar
purposes, in [68], authors use an autoregressive AR(1) model. From a perspective in which the aim is
to resolve the mean and variance of blood glucose levels, for the purposes of prediction, the model that
we develop in this paper can be viewed as a generalized AR(1) model. A standard AR(1) model uses
only the BG measurements and provides predictions based on the information obtained from this data.
With the model we develop here, in addition to the blood glucose measurements, we use nutrition
and external insulin data to account for non-stationarity in the environment, and calculate the effects
of nutrition and external insulin on the discrete time-series by means of an underlying continuous
time model. In this sense, we aim to achieve and enhance what an ARIMA process can do by using
an underlying continuous-time mechanistic model to describe known, and measured, environmental
factors. Moreover, by constructively formulating the functional form of a model embedded with
hard-coded physiological mechanisms, we are hoping to provide both a pathway for incorporating
external physiological knowledge—reducing the data required to estimate the model—and a modeling
framework that, being based in physiology, is likely to be more interpretable to humans working in
systems physiology and in a clinic.
All of these different models, and the algorithms that stem from them, demonstrate significant
diversity in the dynamics of the glucose-insulin system between individuals. This highlights the
importance of personalized models for parameter inference, prediction and control, using data collected
from individual patients or perhaps, once more data is gathered, by clustering patients and using
representative parameter settings from the appropriate cluster. Many of the models described have so
many unknown parameters that it is very hard to use them in such realistic settings. Recently, some
researchers have started to address the applicability of the models in the real patient-data setting
[70, 14, 91] and these papers demonstrate some of the difficulties which arise. In this paper, we aim
to develop a simple interpretable mathematical model that, in view of its interpretability, can be used
safely for glucose prediction and control, and in view of its simplicity, can be trained on patient data.
We concentrate primarily on the T2DM and ICU settings, and comment briefly on the relevance of
our modeling approach for type one diabetes (T1DM).
1.3 Our Contribution
• We describe a simple, interpretable, modeling framework limited to states and parameters that
are directly observable or inferable from data for prediction within the human glucose-insulin
system, based on a continuous time linear, Gaussian, stochastic differential equation (SDE) for
glucose dynamics, in which the effect of insulin appears parametrically.
• We completely describe and detail the inference machinery necessary—in a data assimilation
and inverse problems framework—to estimate a stochastic differential equation model of glucose
dynamics with real-world data.
• The framework is sufficiently general to be usable within the ICU, T2DM and potentially T1DM
settings.
• We demonstrate, in a train-test set-up, that the models are able to fit individual patients with
reasonable accuracy; both ICU and T2DM data are used. The test framework we use is a
predictive one laying the foundations for future control methodologies.
• Comparison of the data fitting for T2DM and ICU patients reveals interesting structural differ-
ences in their glucose regulation.
• We make a comparison of the predictive power of our stochastic modeling framework with that
of more sophisticated models developed for both T2DM and the ICU, demonstrating that the
simple stochastic approach is generally more accurate in both settings.
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1.4 Outline
An outline of the paper is as follows. In Section 2, we introduce the general continuous-time mathe-
matical model that describes the human glucose-insulin system. Then, in Section 3, we introduce the
specific versions of this model relevant in T2DM and ICU settings. The two model classes all derive
from a single general model, and differ according to how nutrition uptake and glucose removal are
represented. In Section 4, we construct the framework for stating the parameter estimation problem
and its solution. In Section 5, we describe the datasets, the experiments we design for parameter
estimation and forecasting, and the methods we use for parameter estimation and forecasting for
the T2DM and ICU settings. Section 6 presents the numerical results on parameter estimation and
forecasting along with some uncertainty quantification (UQ) results separately for T2DM and ICU
settings. Finally, in Section 7, we make some concluding remarks and discuss future directions that
we intend to pursue.
2 Continuous-Time Model
We begin by providing a constructive explanation of the continuos-time model including the model
equations, the description of unknown model parameters and the precise role of each component of
the model. Then, we also provide a detailed conceptual explanation of how a stochastic modeling
approach could be used to represent blood glucose dynamics.
2.1 Components of the Model
In accordance with our goal, which is to develop a highly simplified yet interpretable model, we
work with a forced SDE of Ornstein-Uhlenbeck type to describe glucose evolution, together with an
observation model of linear form, subject to additive Gaussian noise. The Gaussian structure allows
for computational tractability in prediction since probability distributions on the glucose state are
described by Gaussians and hence represented by simply a mean and variance. Note that the protocols
for managing glucose depend on intervals; e.g., a goal may be to keep glucose between 80-150 mg/dl
and interval deviation from this goal, e.g., 151-180 mg/dl, induce changes in the insulin dosage. This
means that decisions are made based on boundaries of glycemic trajectories. Nevertheless, because
glucose oscillates under continuous feeding, clinicians typically aim to ensure that the glycemic mean
does not fall below 60 mg/dl or above 180 mg/dl for any length of time. The intervals are then a proxy
for this balance of managing the mean and protecting against trajectories diverging too high or low at
any time, including between observations. Hence accurately resolving mean and standard deviation in
BG levels is extremely important. Furthermore the Kalman filter may be used to incorporate the data,
and also works entirely within the Gaussian framework; and finally parameter learning, although non-
Gaussian, is well-developed in the Kalman filter setting, both from the fully Bayesian and optimization
(empirical Bayes) perspectives. The Ornstein-Uhlenbeck process has three contributions: a damping
term which drives the BG level towards its base value at a rate which is possibly insulin dependent;
a forcing representing nutritional intake and a white noise contribution, which is used to encapsulate
the high-frequency dynamics as these dynamics are difficult to be resolved with sparse measurements.
The presence of noise in the glucose evolution model, as well as in the data acquisition process, allows
for model error which is natural in view of the the rather simple modeling framework. We obtain the
following model for the evolution of blood glucose G(t):
Ġ(t) = −γ(G(t)−Gb) +m(t)− βI(t) +
√
2γσ2Ẇ (t). (2.1)
The BG level at time t is measured in the units of mg/dl, I(t) is the rate of intravenous insulin
(insulin iv) at time t in the units of U/min where U is the insulin unit, and m(t) is the meal function
representing the rate of glucose intake at time t in the units of mg/(dl*min). Here, W (t) is a Brownian
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motion and describes variations in the BG level G(t) which are not encapsulated in the simple damped-
driven exponential decay model that we use here.
In our approach, we use the stochastic differential equation as stated in (2.1). In this model, Gb
represents the basal glucose value in mg/dl units and γ is the decay rate of BG level to its basal
value with its own effect in the units of 1/min, β is a proportionality constant for the effect of insulin
iv on the BG level in the units of mg/(dl*U), and σ is the variance of the oscillations. We will use
simple models for the meal function m(t) and the insulin delivery function I(t) that will enable explicit
solution of the continuous time model between events; events in our model are times at which the
meal function or insulin delivery function change discontinuously, or points at which BG is measured.
The precise notation will be given below. The simple structure of Brownian motion W (t) means
that, when integrated, it will lead to normally distributed random variables in discrete time, with
analytically calculable means and variances. The model is thus highly tractable. The equation given
in (2.1) is analytically solvable, meaning that we can write a formula in continuous time that gives the
BG level at any time t, the output of the system, as a function of the nutrition and insulin delivered
up to time t, the inputs to the system. For computational purposes, and because data is typically
available in discrete time, we need the discrete-time version of the model (2.1). The time discretization
is defined completely by the dataset in the following sense. Let {t(m)k }
Km
k=1 denote the starting time
of meals in the T2DM setting and the (discontinuous) nutrition level change in the ICU setting. Let
{t(i)k }
Ki
k=1 denote the (discontinuous) insulin iv level change times in ICU setting. Finally, let {tok}
Ko
k=1
denote the measurement (observation) times in both settings. We call the re-ordered union of these
sets, {tk}Nk=0 := {t
(m)
k }
Km
k=1 ∪ {t
(i)
k }
Ki
k=1 ∪ {tok}
Ko
k=1, to be the event times, which naturally identify the
time discretization. In order to make use of analytical tractability of the model (2.1) and account
for the fact that event times occur at discrete, irregular times, we obtain the discrete-time version by
integrating (2.1) over the event-time intervals, [tk, tk+1), k = 0, 1, ..., N − 1, and refer to the resulting
model as the event-time model.
We will exhibit the differing versions of the general event-time model for T2DM and ICU settings
in more detail in the following sections, but here we make a general overarching observation about
the form of the event-time model. If we integrate (2.1) over [tk, tk+1), with use of Itô formula,
1 we
obtain that
G(tk+1) = Gb + e
−γhk(G(tk)−Gb) +
∫ tk+1
tk
e−γ(tk+1−s)m(s)ds−
∫ tk+1
tk
e−γ(tk+1−s)I(s)ds
+ σ
√
1− e−2γhkξk,
(2.2)
where hk := tk+1 − tk and ξk ∼ N(0, 1) independent random variables for k = 0, 1, ..., N − 1.
2.2 Conceptual Explanation of How the Stochastic Model Represents Glu-
cose Physiology
The model we propose represents blood glucose dynamics broadly with two classes of terms, determin-
istic components and stochastic components. The deterministic terms govern the mean through both
endogenous and exogenous factors. For example, the mean, equilibrium, or homeostasis for blood
glucose, represents one of the endogenous relationships between glucose and insulin through the basal
rate. Similarly, changes in the mean are also controlled by the deterministic component but here due
to exogenous drivers such as nutrition or administered insulin. The stochastic class governs the faster
time-scale fluctuations about the deterministically specified mean. The glycemic fluctuations due to
endogenous factors are assumed to be mean zero, independent of the value of the blood glucose, and
are mean-reverting to the basal rate. In this way, the range of the glycemic fluctuations represent the
endogenous glucose-insulin oscillatory dynamics that are often difficult to resolve given the sampling
rate. Effectively, the glycemic fluctuations due to endogenous insulin, random effects, and moderate
1equivalent to using integrating factors in this case
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changes in activity–e.g., walking from a car to a restaurant—are modeled as fast time scale random
fluctuations of glucose.
More explicitly, the deterministic governing terms of the model determine the rate of change of
mean blood glucose level. The first deterministic term, −γ(G(t) − Gb), in the general version of
the model given in (2.1), represents the endogenous regulation; either by consumption or by secreted
insulin, to revert blood glucose level to its person-specific basal glucose value, Gb, with a person-specific
rate, γ. In the absence of nutrition and exogenous insulin, the basal value represents the mean blood
glucose level that all glycemic trajectories fluctuate around, and are reverted to. The second category
of deterministic terms—including +m(t)—represents and quantifies the effect of exogenous nutrition
on the rate of change of the blood glucose level. Nutrition increases the rate of change and cause the
blood glucose level to increase as the rate and amount of exogenous nutrition delivery increases. The
third category of terms—including −βI(t)—represents the effect of exogenous insulin on the rate of
change of the blood glucose level. Exogenous insulin drives the rate of glucose use to increase, causing
the blood glucose level to decrease. Both the second and third classes of terms are able to shift the
glycemic equilibrium depending on their amount and the length of time they are present and effective.
The stochastic governing terms of the model determine the fast-time scale fluctuations about the
mean blood glucose level, effectively determining the variance of the glycemic fluctuations about the
mean. These fluctuations are formulated to be continuous in time random processes that are specified
only by amplitudes—their coordinates are variances rather than an exact glucose position—implying
that the true trajectory of the blood glucose level is never resolved but with oscillations or fluctuation
amplitudes. In this way we are assuming that the glycemic fluctuations due to endogenous factors, e.g.,
glycemic fluctuations due to small amounts of movement, are captured by the random terms in the
model. Because we do not have data to resolve the existence or source of these glycemic fluctuations,
we are effectively considering the unresolvable glycemic fluctuations to be random effects. Larger
changes in a mean, e.g., via exercise, would be controlled by the deterministic components of the
model. We do not include a term that could account for more vigorous exercise explicitly because we
do not collect data that would allow such a term to be inferred. It is possible that a combination of
existing deterministic and stochastic parameters, e.g., γ that controls the rate of return to basal, are
enough to fully explain exercise-based variation in blood glucose, but as we do not currently have the
data to evaluate this question, we cannot evaluate success or failure of the model’s ability to account
for exercise.
There is an interplay between the stochastic and deterministic components of the model. For
example, while the movement of the mean is controlled by the deterministic terms, reversion to the
mean is controlled both by deterministic and stochastic terms. Meaning, the ability of the body to
regulate glucose homeostasis by endogenous means via the reversion to the mean is controlled by both
the deterministic and the stochastic terms.
It is clear that this model has limiting factors; the key question is, how do these limiting factors
affect our ability to predict blood glucose and the body’s response to exogenous inputs. Of particular
importance is an understanding of what fidelity is lost, and what features are differently resolvable
with the stochastic and the non-stochastic models.
Note also that from another perspective, the resulting SDE model may also be considered as a more
sophisticated version of the ARIMA-type models (referenced in the earlier literature review) which
are used to describe stochastic processes generally with the aim of analyzing data and/or forecasting
future values. More precisely, the model given in (2.2) can be thought as an ARIMA model with
specific interpretable and time inhomogeneous coefficient structure. Adopting this point of view can
be interpreted as using the simplicity of ARIMA models but formulating the parametric dependence
of the coefficients in such a way that the resulting model is also a representative of the underlying
physiology.
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3 Event-Time Model
In this section, we show how the general continuous-time model (2.1) takes specific forms in the T2DM
and ICU settings. In Sections 3.1 and 3.2, we define the specific meal function for each case and derive
the final discrete-time model, which we refer to as the event-time model. Note also that the focus
of our data-driven studies here are the ICU and T2DM patients. The development of an analogous
T1DM model is not considered here and is left for future work.
The general model in (2.1) takes different forms when it is stated in different settings. For example,
in the ICU setting, the meal function m(t) is a piecewise constant function describing a constant rate
of nutrition. It is important to note that because of the way that the nutrition is delivered to the ICU
patients, it is a reasonable modeling choice to use a piecewise constant function, made quantitative
using the raw nutrition data (i.e., the amount of carbohydrates) to model the effect of nutrition on
the blood glucose level. Moreover, as we will explain in more detail in Section 7, attempts at using a
smoother function, to mimic gradual decrease in the effect of nutrition delivery on blood glucose level,
did not yield better forecasting results. On the other hand, in the T2DM setting, our dataset includes
the total glucose amount ingested at each meal, and through initial experiments with simpler models,
we determined that in this context it is important to model the time-history of the resulting glucose
intake as this happens in a more complicated fashion than for ICU patients. To this end we use a
function consisting of the difference of two exponential functions to model the effect of each meal on
the blood glucose level in a realistic manner. That is, for each meal, the effect of the nutrition on
the blood glucose level (proportionally to the carbohydrate amount in the meal) initially increases
monotonically, reaches a peak value after a time on the order of an hour, and then starts to decrease to
an negligible level over a time on the order of hours. This behavior, namely, how long it takes to reach
the peak value and how long it takes to effectively disappear from the system, is characterized by two
unknown model parameters; these are estimated from the data. More details about this function are
given in Section 3.1. Taking into account all of these sorts of differences, we state the “event-time”
version of the continuous general model in (2.1).
3.1 T2DM
In this setting, we will consider a system that is driven by nutrition. Namely, the only input to the
model in its current version is the nutrition. That is, we are developing a T2DM model assuming
that individuals do not inject insulin, since none of the patients in our dataset use subcutaneous
insulin. However, we could easily modify the model to include injectable insulin. Note that besides
incorporating the effect of injectable insulin into the model, we will also modify it to account for the
use of drugs such as metformin. So, in this setting we choose to model glucose removal to occur at a
constant rate γ, setting β = 0; the variable I(t), which represents the rate of insulin iv, does not enter
the model at all. On the other hand, the “meal function”, m(t) in this case requires to make some
additional modeling decisions as briefly described above. In order to model the glucose input from
each meal into the system, we use the difference of two exponential functions. There are two reasons
for making this choice. The first is to describe the uptake of glucose into the bloodstream via ingestion
through the stomach, and the second is to have a smooth function of model parameters from which
we will benefit when performing parameter estimation from data. Note that using a smooth function
to model glucose intake has a substantial impact on inference, and the details about the choice of this
function will be discussed later in Section 7. Now, recall that {t(m)k }
Km
k=1 denotes the starting time of
the meals over the whole time interval that we work on. Then, we define
m(t) =
Km∑
k=1
Gk
ck
(e−a(t−t
(m)
k ) − e−b(t−t
(m)
k ))χ
[t
(m)
k ,∞)
(t) (3.1)
where Gk is the total amount of glucose (mg/dl) in the k
th meal, and ck is normalizing constant so
that
∫∞
t
(m)
k
(e−a(t−t
(m)
k ) − e−b(t−t
(m)
k ))dt = 1, for k = 1, 2, ...,Km. Also, χA(·) is called the characteristic
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function and defined as follows
χA(x) =
{
1, x ∈ A,
0, x /∈ A.
Therefore, the model in (2.1) becomes
Ġ(t) = −γ(G(t)−Gb) +
Km∑
k=1
Gk
ck
(e−a(t−t
(m)
k ) − e−b(t−t
(m)
k ))χ
[t
(m)
k ,∞)
(t) +
√
2γσ2Ẇ (t), (3.2)
in the T2DM setting. In this model, the first term represents body’s own effect to remove insulin from
the bloodstream, the second term represents the effect of nutrition on the rate of change of BG, and
the last term models the oscillations in the BG level. Integrating over [t0, t], we can write the analytic
solution of this equation as
G(t) = Gb + e
−γ(t−t0)(G(t0)−Gb)
+
Km∑
k=1
Gk
ck
(
e−a(t−t
(m)
k ) − e−γ(t−t
(m)
k )
γ − a
− e
−b(t−t(m)k ) − e−γ(t−t
(m)
k )
γ − b
)
χ
[t
(m)
k ,∞)
(t)
+
∫ t
t0
e−γ(t−s)
√
2γσ2dW (s).
(3.3)
Note that, in practice, we need to evaluate BG level at specific time points and hence need the
discrete-time model implied by the continuous time representation in (3.3). Now, by integrating (3.2)
over [tk, tk+1) and denoting gk := G(tk) for k = 0, 1, ..., N , we obtain
gk+1 = Gb + e
−γhk(gk −Gb) +mk + σ
√
1− e−2γhkξk, k = 0, 1, 2, ..., N − 1, (3.4)
as a special case of (2.2). Also, for any fixed tk, find the meal times t
(m)
j such that t
(m)
j ≤ tk and
denote the index set of these meal times by Ik. Then mk in (3.4) becomes
mk =
∑
j∈Ik
Gj
cj
(
e−a(tk+1−t
(m)
j ) − e−γhke−a(tk−t
(m)
j )
γ − a
− e
−b(tk+1−t(m)j ) − e−γhke−b(tk−t
(m)
j )
γ − b
)
, (3.5)
for k = 0, 1, 2, ..., N −1. Hence, note that in this case, we have five model parameters to be estimated:
Gb, γ, σ, a, b. Recall that in this setting, Gb represents the basal glucose value that BG level stays
around starting some time after nutrition intake until the next nutrition intake. γ represents the
decay rate of BG level to Gb after the nutrition intake, and σ represents the amplitude of the BG level
oscillations. The parameters a and b entering the meal function implicitly control the time needed
for the glucose nutrition rate to reach its peak value, and the time needed for this rate to return
back to the vicinity of 0. Because of these simple physiological meanings, the parameters entering the
event-time model are important not only for accurately capturing, and predicting, glucose dynamics
based on data, but also contain implicit information about the health condition of the patient. For
example, the basal glucose value is measured during some tests to check if an individual is healthy,
pre-diabetic, or diabetic.
3.2 ICU
In the ICU setting real data is available for both nutrition and insulin iv. Nutrition is typically
delivered through enteral feeding tube, which is a mechanism to deliver nutrition via a tube entering
to the mouth and running to the gut. On the other hand, 8-10% of the ICU patients are diabetic
and only 5% of those are T1DM patients. However, more than 90% of ICU patients require glycemic
management and 10-20% of them experience a hypoglycemic event over the course of management.
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Consequently, regardless of being diabetic or non-diabetic, they are typically given insulin iv to control
BG levels. For simplicity, and because it is a reasonable approximation of reality, i.e., insulin iv and
tube feed are delivered at a constant rate we approximate both nutrition and insulin as piecewise
constant functions. Furthermore, in contrast to the situation for T2DM, we do not set β = 0 unless
patient is not delivered insulin iv.
In this case {t(m)k }
Km
k=1 represents the change of rate times for nutrition and the meal function
becomes
m(t) =
Km∑
k=1
dkχ[t(m)k ,t
(m)
k+1)
(t), (3.6)
where dk is the nutrition rate over the time interval [t
(m)
k , t
(m)
k+1), k = 1, ...,Km, that is directly obtained
from the dataset. Remember that the insulin rate function, I(t) is also a piecewise constant function,
which we formulate as
I(t) =
Ki∑
k=1
ikχ[t(i)k ,t
(i)
k+1)
(t), (3.7)
where ik is the rate of insulin over the time interval [t
(i)
k , t
(i)
k+1), again obtained directly from the data
set.
Therefore, substituting (3.6) and (3.7) into the general equation (2.1), the ICU version of our
model becomes
Ġ(t) = −γ(G(t)−Gb) +
Km∑
k=1
dkχ[t(m)k ,t
(m)
k+1)
(t)− β
Ki∑
k=1
ikχ[t(i)k ,t
(i)
k+1)
(t) +
√
2γσ2Ẇ (t). (3.8)
In this model, the first term models the glucose removal rate with body’s own effort (γ), the second
term shows the effect of nutrition on the BG level, the third term, βI(t), models the external insulin
effect, and the last term models the oscillations in the BG level.
Now, integrate (3.8) to get the analytical solution for any t ≥ t0 as follows
G(t) = Gb + e
−γ(t−t0)(G(t0)−Gb) +
Km∑
k=1
dk
∫ t
t0
e−γ(t−s)χ
[t
(m)
k ,t
(m)
k+1)
(s)ds
− β
Ki∑
k=1
ik
∫ t
t0
e−γ(t−s)χ
[t
(i)
k ,t
(i)
k+1)
(s)ds+
√
2γσ2
∫ t
t0
e−γ(t−s)dW (s).
(3.9)
For the same reasons explained in the T2DM setting, we will put together all event times and
rewrite the meal function, m(t), and the insulin function, I(t), with respect to this new discretization
of the time interval. Then, once again, using the same notation, and integrating (3.8) over [tk, tk+1),
we obtain the discrete version as follows:
gk+1 = Gb + e
−γhk(gk −Gb) +
1
γ
(1− e−γhk)dk − β
1
γ
(1− e−γhk)ik + σ
√
1− e−2γhkξk,
k = 0, 1, 2, ..., N − 1,
(3.10)
as another special case of (2.2). Note that in this case, we have four model parameters to estimate:
Gb, γ, σ, β. Remember once again, Gb is the basal glucose value and γ is the decay rate of the BG
level to its basal value, and σ is a measure for the magnitude of the BG oscillations. Finally, β
is another proportionality constant, which is used to scale the effect of insulin iv on the BG rate
change appropriately. These four parameters represent physiologically meaningful quantities that
could properly resolve the mean and variance of the BG level.
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4 Parameter Estimation
Our goal in this section is to formulate the parameter estimation problem. In Section 4.1, we construct
an overarching Bayesian framework for our parameter estimation problems. We then describe two
solution approaches for this problem: an optimization based approach which identifies the most likely
solution, given our model and data assumptions; and MCMC, which samples the distribution on
parameters, given data, under the same model and data assumptions. These two solution approaches
are detailed in Sections 4.2 and 4.3, respectively.
As shown in detail before, our model takes slightly different forms in the T2DM and ICU settings.
In the former the model parameters to be estimated are Gb, γ, σ, a, b whereas in the latter the unknown
parameters are Gb, γ, σ, β. However, we adopt a single approach to parameter estimation. To describe
this approach we let the vector, θ represent the unknown model parameters to be determined from
the data, noting that this is a different set of parameters in each case. Many problems in biomedicine,
and the problems we study here in particular, have both noisy models and noisy data, leading to a
relationship between parameter θ and data y of the form
y = G(θ, ζ) (4.1)
where unknown ζ is a realization of a mean zero random variable, but its value is not known to us.
The objective is to recover θ from y. We will show how our models of the glucose-insulin system lead
to such a model.
4.1 Bayesian Formulation
The Bayesian approach to parameter estimation is desirable for two primary reasons: first it allows
for seamless incorporation of imprecise prior information with uncertain mathematical model and
noisy data, by adopting a formulation in which all variables have probabilities associated to them;
secondly it allows for the quantification of uncertainty in the parameter estimation. Whilst extraction
of information from the posterior probability distribution on parameters given data is challenging,
stable and practical computational methodology based around the Bayesian formulation has emerged
over the last few decades; see [76]. In this work, we will follow two approaches: (a) obtaining the
maximum a posteriori (MAP) estimator, which leads to an optimization problem for the most likely
parameter given the data, and (b) obtaining samples from the posterior distribution on parameter
given data, using Markov Chain Monte Carlo (MCMC) techniques.
Now let us formulate the parameter estimation problem. Within the event-time framework, let
g = [gk]
N
k=0 be the vector of BG levels at event times {tk}Nk=0, and y = [yk]
Ko
k=1 be the vector of
measurements at the measurement times {t(o)k }
Ko
k=1 ⊂ {tk}Nk=0. By using the event-time version, and
defining {ξk}Nk=0 to be independent and identically distributed standard normal random variables, we
see that given the parameters θ, g has multivariate normal distribution, i.e., P(g|θ) = N(m(θ), C(θ)).
Equivalently,
g = m(θ) +
√
C(θ)ξ, ξ ∼ N(0, I). (4.2)
Let L be a Ko× (N+1) matrix that maps {gk}Nk=0 to {yk}
Ko
k=1. That is, if a measurement i ∈ 1, ...,Ko
is taken at the event time tj , j ∈ 0, 1, ..., N , then the ith row of L has all 0’s except the (j + 1)st
element, which is 1. Adding a measurement noise, we state the observation equation as follows:
y = Lg +
√
Γ(θ)η, η ∼ N(0, I), (4.3)
where Γ(θ) is a diagonal matrix representing the measurement noise. Thus, we obtain the likelihood
of the data, given the glucose time-series and the parameters, namely
P(y|g, θ) = N(Lg,Γ(θ)).
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However, when performing parameter estimation, we are not interested in the glucose time-series itself,
but only in the parameters. Thus we directly find the likelihood of the data given the parameters
(implicitly integrating out g) by combining (4.2) and (4.3) to obtain
y = Lm(θ) +
√
S(θ)ζ, ζ ∼ N(0, I), (4.4)
where S(θ) = LC(θ)LT + Γ(θ). Since ζ has multivariate normal distribution, using the properties of
this distribution, we find that given the parameters, θ, y also has multivariate normal distribution
with mean Lm(θ) and covariance matrix S(θ). This is the specific instance of equation (4.1) that
arises for the models in this paper.
We have thus obtained P(y|θ) = N(Lm(θ), S(θ)), that is,
P(y|θ) = 1√
(2π)Km det(S(θ)))
exp
(
−1
2
(y − Lm(θ))TS(θ)−1/2(y − Lm(θ))
)
; (4.5)
this is the likelihood of the data, y, given the parameters, θ. Also, since we prefer to use − log(P(y|θ))
rather than directly using P(y|θ) for the sake of computation, we state it explicitly as follows:
− log(P(y|θ)) = Km
2
log(2π) +
1
2
log(det(S(θ))) +
1
2
(y − Lm(θ))TS(θ)−1(y − Lm(θ)). (4.6)
Moreover, by using Bayes Theorem, we write
P(θ|y) = P(y|θ)P(θ)
P(y)
∝ P(y|θ)P(θ). (4.7)
Note that the second statement of proportionality follows from the fact that the term, P(y), on the
denominator is constant with respect to the parameters, θ, and plays the role of a normalizing constant.
From another point of view, considering (4.2) and (4.4), we see that given θ, (g, y) has multivari-
ate normal distribution with mean and covariance matrix that could be computed from the above
equations since, given θ, everything is explicitly known. Then, integrating g out, in other words,
computing the marginal distribution we obtain the distribution of y|θ, which corresponds to the one
stated in (4.4).
Now, to define the prior distribution P(θ) we assume that the unknown parameters are distributed
uniformly across a bounded set Θ and define
P(θ) =
1
|Θ|
χΘ(θ) =
{
1
|Θ| , θ ∈ Θ,
0, θ /∈ Θ,
(4.8)
where χΘ(·) is the characteristic function, as defined above and |Θ| is the volume of the region defined
by Θ. Thus, by substituting the likelihood, (4.5), and the prior distribution, (4.8), into (4.7), we
formulate the posterior distribution as follows
P(θ|y) = 1
|Θ|
√
(2π)Km det(S(θ)))
exp
(
−1
2
(y − Lm(θ))TS(θ)−1/2(y − Lm(θ))
)
χΘ(θ). (4.9)
Now, we will show how we use this posterior distribution to state the parameter estimation problem.
4.2 Optimization
In this approach, the goal is to determine parameter values, θ, which maximize the posterior distri-
bution, P(θ|y) and is called to be the MAP estimator. Using the prior distribution as specified above,
the parameter estimation problem becomes
θ∗ = arg max
θ
P(θ|y) = arg max
θ∈Θ
P(y|θ) = arg min
θ∈Θ
− log(P(θ|y)). (4.10)
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Then, substituting (4.6) into (4.10), the problem will take the form
θ∗ = arg min
θ∈Θ
||S(θ)−1/2(y − Lm(θ))||2 + log(det(S(θ))). (4.11)
Hence, placing uniform prior distribution turns the problem of finding the MAP estimator into a
constrained optimization problem. To solve this problem, we use built-in MATLAB functions, such as
fmincon and multistart. fmincon is a gradient-based minimization algorithm for nonlinear func-
tions. multistart starts the optimization procedure from the indicated number of starting points
that are picked uniformly over the region defined by the constraints. It uses fmincon and other simi-
lar type of algorithms to perform each optimization process independently and provides the one that
achieves the minimum function value among the result of all separate runs. With this approach, we
have the opportunity to compare different optimization procedures that starts from different initial
points. This provides some intuitive understanding of the solution surface and hence the estimated
optimal parameters.
4.3 MCMC
Once an optimal point has been found, we may also employ the Laplace approximation [56, 62]
to obtain a Gaussian approximation to the posterior distribution. The Laplace approximation is a
reasonable approximation in many data rich scenarios in which all parameters are identifiable from the
data, because of the Bernstein Von Mises Theorem [81], which asserts that the posterior distribution
will then be approximately Gaussian, centered near the truth and with variance which shrinks to zero
as more as more data is acquired. However data is not always abundant, and not all parameters
are identifiable even if it is; in this setting sampling the posterior distribution is desirable. MCMC
methods are a flexible set of techniques which may be used to sample from a target distribution,
which is not necessarily analytically tractable, [54, 69]. For example, the distribution P(θ|y) is the
conditional distribution of the random model parameters, θ given the data, y. Even though we can
explicitly formulate it as in equation (4.7), it is not always an easy task to extract useful quantities,
such as posterior mean and variance, from that formula. In such cases, MCMC techniques are used to
generate random samples from this target distribution and this random sample is used to obtain the
desired information, which could be anything such as the mean, mode, covariance matrix, or higher
moments of the parameters. Moreover, this technique is also very helpful to obtain UQ results for the
estimated parameters.
In order to obtain more extensive knowledge than MAP estimator can provide about the posterior
distribution of parameters given the data, θ|y, we use MCMC methods as a natural choice to sample
from that distribution. Among different possible algorithms (see [29]), we use the standard random
walk Metropolis-Hastings algorithm. In order to make sure the resulting sample is indeed a good
representer of the posterior distribution, we perform some diagnostics such as checking if chains for
each parameter converged and if they are uncorrelated. Then, after removing the burn-in period,
we compute the mean and the covariance matrix fro the remaining part of the sample. We use the
mean as a point estimator for simulation and forecasting, and the covariance matrix provided valuable
information to quantify uncertainty for the estimated parameters.
In general, it is hard to obtain efficient results with MCMC methods even when sampling from
the joint distribution of four or five parameters, due to the issues such as parameter identification.
Moreover, obtaining accurate results with this approach requires careful choice of starting point and
tuning some other parameters. In general the performance of the algorithm will depend on the initial
point. We tested the use of both random starting points and MAP estimators as starting point. The
former enables us to detect when several modes are present in the posterior distribution; the latter
helps to focus sampling near to the most likely parameter estimate and to quantify uncertainty in it.
However, it is also important to note that using MAP estimator as a starting point is not helpful in
all cases. More precisely, if the MAP estimator is not a global minimum but a local minimum, then
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the chain could get stuck around this point. Therefore, it requires careful analysis, comparison and
synthesis of the results obtained with these different approaches.
5 Methods, Datasets, and Experimental Design
In this section, we describe the datasets that we have in the T2DM and ICU settings, the experiments
that we design to present our numerical results, and the methods that we follow to perform parameter
estimation and forecasting. Depending on the specifics of each case and to reflect the real-life situation,
we designed slightly different experiments in the T2DM and ICU settings. However, the mathematical
solution approaches for parameter estimation and forecasting stay the same for both settings because
we use similar mechanistic models. In this opening discussion we first describe the features that are
common to both the T2DM and the ICU settings. The two following subsections 5.1, 5.2 then detail
features specific to each of the two cases.
Because we use a linear, Gaussian stochastic differential equation to model the BG level, our
forecast is a Gaussian characterized by its mean and standard deviation. Hence, rather than having
a point estimate for the future BG levels, we obtain a normal random variable for each prediction.
In testing predictions of the model it is natural to check if 1− and 2− stdev intervals around the
respective means capture the true BG levels. Note that the probability of a Gaussian random variable
to take values within 1− and 2− stdev regions around its mean are ∼ 68% and ∼ 95%, respectively.
We define the observational noise covariance Γ(θ), defined in (4.3), to be a diagonal matrix with
form diag(Γ(θ)) := λ ∗Lm(θ). Whilst we could estimate λ alongside θ, from the data, we have chosen
a heuristic to set it in advance. Specifically we found that above a value of around 0.3 all forecasts
were very noisy and contained little predictive value; on the other hand, below 0.3 results appeared
to be fairly robust to the value chosen for λ; in all the experiments presented in Section 6 we choose
λ = 0.1.
5.1 T2DM
5.1.1 Model, Parameters, and Dataset
In this setting, we use the model (3.4) with the function mk defined as in (3.5). Hence, there are
five parameters to be estimated: basal glucose value, Gb, BG decay rate γ, the measure for the
amplitude of BG oscillations, σ, and a and b, which are the parameters implicitly modeling the
time needed for the rate of glucose in the nutrition entering the bloodstream to reach its maximum
value and the total time needed for this rate to decrease back to 0. We assume that the prior
distribution is non-informative and initially the parameters are independent, except for a constraint
on the ordering of a and b. We determine realistic lower and upper bound values for each of them,
define Θ′ := [0, 750]× [0, 5]× [0, 100]× [0.01, 0.05]× [0.01, 0.05] (in the order of Gb, γ, σ, a, b), and then
define Θ from Θ′ by adding the constraint a < b. We thereby form the prior distribution as defined
in (4.8). Recall that these bounds define the constraints employed when we define the parameter
estimation problem in the optimization setting for the MAP point. The set Θ is determined from
clinical and physiological prior knowledge, and by simulating the model (3.2) and requiring realistic
BG levels. Data are collected from three different T2DM patients. For each patient the dataset
consists of the meal times, the glucose amount in the meal and BG measurements along with the
measurement times. More detailed information on the dataset such as number of measurements,
recorded meals, and mean glucose value over training, testing or over entire data sets can be found in
Table 5.1.
5.1.2 Parameter Estimation and Uncertainty Quantification
We perform parameter estimation for three patients separately. First, we estimate parameters by using
data over four consecutive, non-overlapping time intervals with optimization and MCMC approaches.
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Besides estimated values, we also provide UQ results. In the optimization setting, we use the Laplace
approximation as discussed at the start of subsection 4.3. The optimal parameters determine the
mean of the Gaussian approximation, and the inverse of the Hessian matrix becomes the covariance
matrix, providing the tools for UQ. In the MCMC approach, we use the resulting random samples for
UQ.
5.1.3 Forecasting
We adopt a train-test set-up as follows. Since the health conditions of the T2DM patients are unlikely
to change over time intervals that are on the order of days, we design an experiment in which we use
one week of data for training the patient-specific parameters. Then, we use the estimated parameters
to form a patient-specific model and use this model to forecast BG levels for the following three weeks,
using the known glucose input through the meals; this leads to a three-week testing phase. From a
practical patient-centric point of view this leads to a setting in which forecasting BG levels for the
following three weeks requires patients to collect BG data for only one week in every month, and
then the patient-specific model will be able to capture their dynamics and provide forecasts based on
nutrition intake data over the rest of the month.
5.2 ICU
5.2.1 Model, Parameters, and Dataset
In the ICU setting, we use the model (3.10), and there are now four parameters to be estimated: basal
glucose value, Gb, BG decay rate, γ, the parameter used to quantify the amplitude of the oscillations
in the BG level, σ, and a proportionality constant, β to scale the effect of insulin IV on the BG level.
Similar to what we did in the T2DM setting, we find realistic lower and upper bounds for the unknown
parameter values and set Θ := [0, 750]× [0.02, 1]× [0, 100]× [20, 110] to obtain the prior distribution
as defined in (4.8). In this case, we impose two further linear constraints, namely Gb − 3.5 ∗ β < 115
and β − 1110γ < 10. These constraints are imposed to ensure that the model predictions remaining
biophysically plausible, and are determined simply by forward simulation of the SDE model; the
resulting inequality constraints do not overly constrain the parameters in that good fits can be found
Patient ID patient 1 patient 2 patient 3
Total # glucose measurement 304 211 91
Total # meals recorded 122 76 46
Total # days measured 26.6 27.67 28.12
Mean measured glucose 113±25 127±32 124±26
Training set: # glucose measurement 80 53 29
Training set: # meals recorded 26 18 15
Training set: # days measured 7.02 7 7.05
Training set: mean measured glucose 112±25 116±28 125±24
Testing set: # glucose measurement 224 158 31
Testing set: # meals recorded 96 58 62
Testing set: # days measured 19.58 20.67 21.07
Testing set: mean measured glucose 113±25 130±33 123±27
Table 5.1: Information about the data set that is used in the T2DM setting, which is collected from
three different T2DM patients. Note that there is a considerable variability between the data collection
behaviour of each patient, which is also reflected in the number of recorded measurements and meals.
Also, recall that we intentionally used one week of data for training and the following three week of
data for testing.
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which satisfy these constraints, and yet they yield more realistic BG level behavior than solutions
found without them. Thus as in the T2DM case, we the bounds and constraints chosen are based on
physiological knowledge and requiring simulated BG levels resulting from values within the region Θ
to be realistic.
In this case, the dataset consists of the rate of glucose in the nutrition and the rate of insulin
infusion along with the times at which there is a rate change. It also contains the BG measurements
and the measurement times. Summary statistics about the data set that is used in the ICU setting
can be found in Table 5.2. Note that in this case, we used all available data for each patient to perform
parameter estimation and forecasting, and all three ICU patients are non-T2DM.
Patient ID patient 4 patient 5 patient 6
Total # glucose measurement 177 204 271
Total # days measured 13.99 16.8 24.48
Mean measured glucose 141±18 151±32 151±43
Training set: average # glucose measurement 14.13 13.5 14.07
Testing set: average # glucose measurement 1 1 1
Table 5.2: Information about the dataset that is used in the ICU setting, collected from three ICU
patients who are not T2DM. Because of the experiment we designed the training sets are moving with
by overlapping with each other. So, we provide average number of glucose measurements over these
moving windows. Also, since we forecast until the next measurement time following the training time
window, each testing set contains only one glucose measurement. Other information that is included
in Table 5.1, but not here, such as mean measured glucose over training set(s) is neither meaningful
nor helpful in this setting.
5.2.2 Parameter Estimation and Uncertainty Quantification
We use both the optimization and MCMC approaches for parameter estimation in a patient-specific
manner, in this setting, too. However, for UQ, we use only MCMC to estimate the posterior mean
and variance on the parameter; this is because there were cases where it was not appropriate to use
the Laplace approximation, something that will be explained in more detail in Section 6.2.
5.2.3 Forecasting
Patients in the ICU exhibit BG time-series that are very different from T2DM patients; in particular
the time-series is often non-stationary in complex ways and on different time scales. On slower time
scales, patients eventually leave the ICU because their health either improves or declines. But there
can be fast time scale changes too due to interventions and/or sudden health-related events, such as
a stroke. These health changes will lead to changes in the best-fit parameters of the model; in other
words the patient-specific model itself may change abruptly, in contrast to the T2DM case where
changes in the best-fit parameters typically occurs on a much longer time-scale, and reflects gradual
changes in health condition. To avoid compensating for different values of parameters over longer
time intervals, and to make more accurate predictions, we use only one day of data for parameter
estimation in the ICU. Moreover, to construct an experiment that reflects real-life scenarios, we need
be able to estimate the model parameters with smaller size datasets than in the T2DM case, because of
the imperative of regular intervention within the ICU setting, typically on a time-scale of hours. As a
consequence our train-test set-up in this case differs quantitatively from the T2DM case. The training
sets for each patient consist of approximately one day of data over a moving time intervals, with end
points chosen to be BG measurement times. Thus, the time windows are obtained by moving the left
end point to the next BG measurement time and choosing its right end point with the constraint that
it contains approximately one day of data and the new time window is not contained in the previous
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one. So, in this case, there is a large overlap between the consecutive time windows of the training
sets.
On the other hand, because of rapidly changing conditions, forecast of BG levels needs only to be
accurate over shorter time-scales, too. Indeed, in general, it is important to know glycemic dynamics
on the order of hours (not days) to manage the glycemic response of patients. So, for each training
set, the left end point of the time window of the corresponding testing set is chosen to be the right
end point of the time window of the patient’s training set. Then, we choose the right end point of
the test set to be the next BG measurement time. We follow the same procedure over the moving
time intervals to the end of the whole dataset for each patient. Note that from a practical point of
view, this experiment exhibits a real life situation in which we use only one day of data for parameter
estimation and then perform forecasting for the next few hours based on the estimated parameters.
Such a set-up would be desirable as a support to glycemic management of these patients.
5.3 Evaluation Metrics
Before having a closer look at the numerical results in the next section, let us give the definitions of
the statistics that will be used to evaluate and compare the forecasting capability of the models. Let
{yi}Ni=1 denote the true BG measurements over the predefined testing time window for an experiment.
Let {ŷi}Ni=1 denote the forecast at the true measurement time points obtained by a model. Note that
if the model is a stochastic one, {ŷi}Ni=1 represents the mean of the model output, while it is simply the
model output for a deterministic ODE model. When a stochastic model is used, it is natural to obtain
a confidence interval as this may be obtained as a direct consquence of the fact that the model output
is in the form of a random variable; such a model output cannot be obtained for an ODE type of a
model when parameters are learned through optimization. However, by using appropriate parameter
and state estimation techniques, it may again be possible to obtain a similar kind of confidence interval
for the model output which is in the form of a point-estimate. When we have probabilistic forecasts
we let {εi}Ni=1 denote the corresponding standard deviation for each forecast at the true measurement
points so that we can form 1- and 2-stdev bands as [ŷi − εi, ŷi + εi]Ni=1 and [ŷi − 2εi, ŷi + 2εi]Ni=1,
respectively. Then, for each model, we can compute the percentage of true measurements, {yi}Ni=1,
that are captured in their respective 1- and 2-stdev bands. These two percentages will be two of the
evaluation tools that will be used in evaluation below. In addition, in some cases, we will use standard
measures such as mean-squared error (MSE), root-mean-squared error (RMSE) and mean percentage
error (MPE), which are computed as follows.
MSE =
1
N
N∑
i=1
(yi − ŷi)2, RMSE =
√√√√ 1
N
N∑
i=1
(yi − ŷi)2, MPE =
N∑
i=1
|yi − ŷi|
yi
∗ 100.
6 Numerical Results
In this section we present numerical results concerning the simple, yet interpretable, model introduced
in this paper; we refer to this as the minimal stochastic glucose (MSG) model from now on for ease
of exposition. The two primary conclusions are that:
• we can achieve good accuracy forecasting future BG levels in both the T2DM and ICU settings,
and the uncertainty bands with which we equip our forecasts play an important role in this
regard;
• we can learn a substantial amount about the interpretable parameters within the models, with
possible clinical uses deriving from the parameter estimates, and from tracking them over time,
again using the uncertainty measures that accompany them as measures of confidence.
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We justify these conclusions using T2DM self-monitoring data from a previous prospective self-
management trial, and using retrospective ICU data extracted from the Columbia University Medical
Center Clinical Data Warehouse. The combination of simple predictive model and data acquisition
model accounts for the uncontrolled and complex nature of the data, including data sparsity, inac-
curacy, noisiness, non-stationarity, and biases resulting from the health care process [3, 9, 41, 42, 43,
44, 51, 66], whilst also being interpretable and leading to patient-specific parameter inference and
prediction. To forecast BG for individuals we first solve the parameter estimation problem to entrain
the model to the individual, and we present the numerical results in this order. Even though the
MSG model is relatively simple physiologically it is not always identifiable, given data. For example,
having two parameters, γ and β, related to BG decay rate in the ICU context made it hard to identify
these parameters accurately given the sparsity of the data, the non-stationarity of the patient, and the
complexity of the glycemic dynamics. Despite lack of identifiability of some parameters, parameters
as estimated lead to models which are able to forecast and represent the glucose-insulin dynamics. For
example, in both the T2DM and ICU cases, the UQ results along with estimated parameter values
indicate that the estimates of both the basal glucose rate, Gb, and the proportionality constant be-
tween the basal glucose rate and the variance of the glycemic dynamics, α, reflect realistic values with
uncertainties that manage to capture future data but remain narrow enough to potentially delineate
different treatment pathways. To answer whether the parameter estimates, forecasts, and uncertainty
quantification are good enough to impact clinical understand and decision-making or to construct
physiologically-anchored phenotypes [4, 5, 7] would require evaluation, e.g., manual chart review in
conjunction with a qualitative trial of clinical decision-making or a phenotyping analysis respectively.
In the absence of these analyses we will rely on face validity validation [19, 37, 85] of the forecasting
and UQ capturing future measures as well as a host of quantitative measures of forecast accuracy. We
also reemphasize that the parameter estimates themselves may be useful as they carry information
about gradual disease progression (T2DM) and sudden changes in health condition (ICU).
6.1 T2DM
We will start by showing numerical results for parameter estimation and forecasting based on the
real-world data collected from T2DM patients. These results demonstrate the effectiveness of the
MSG model in capturing the patients’ BG dynamics. Specifically the effectiveness is reflected in the
estimated parameter values and in the efficacy in forecasting future BG levels, using these parameters,
over time periods of length up to three weeks.
6.1.1 Parameter Estimation
Our numerical results exhibit three substantive pieces of evidence which support the validity of the
model and its potential effectiveness for both understanding the physiologic state of an individual,
and for forecasting for that individual, in the context of T2DM. First, the estimated model parameter
values and their evolution over time are physiologically meaningful. That is, the estimated values
reflect the patient’s state as evaluated given available data. Moreover, the evolution of the estimated
parameter values over time reflects changes in the patients’ states in a manner consistent with both
the data and what is known about the non-stationary nature of T2DM. Second, the UQ intervals
for the estimated parameters are physiologically plausible and have three features that make the
model potentially useful: (i) relative to the value of the estimated parameter, the UQ intervals are
wide enough to provide information on the reliability of the point estimates of the model parameters
(ii) the UQ intervals evolution over time, demonstrating a sensitivity to time and the ability to
adapt to non-stationary patients, and (iii) the UQ intervals are narrow enough to plausibly be used
to differentiate behavior choices. And third, the UQ and parameter estimation appears to be robust;
different estimation methods arrive at similar results. A comparison of the estimated parameter values
and corresponding UQ intervals obtained using optimization and MCMC are very similar in almost
all of the cases, implying robustness of the estimates and a relative insensitivity to the estimation
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(a) optimization (b) MCMC
(c) optimization (d) MCMC
(e) optimization (f) MCMC
Figure 6.1: Parameter estimation and uncertainty quantification in the T2DM setting. The left-hand
panel is obtained with optimization and the right-hand panel is obtained with MCMC, both are in
a patient-specific manner. It shows that the point estimates obtained with two approaches are very
close to each other in most cases. Also the width of the 1- and 2-stdev intervals, which are obtained
with Laplace approximation (in the optimization case) and directly from the approximate posterior
samples (in the MCMC) setting, are also agreement with each other. In addition, obtaining estimated
values that are in alignment with real physiological values, these results enforces the reliability of the
parameter estimation results.
methodology. Together these features imply that with a reasonable inference scheme this model could
potentially provide useful information for clinical decision making and deeper clinical understanding
of the patient robustly.
To demonstrate that the estimated parameters are physiologically meaningful, consider Figure 6.1
where we see the point estimates as well as UQ intervals for all parameters and all three patients
obtained with optimization and MCMC methods. The estimated basal glucose, Gb, values are in the
21
ranges of ∼ 95 − 105 mg/dl, ∼ 105 − 140 mg/dl, and ∼ 105 − 125 mg/dl over the course of four
weeks for patients 1, 2, and 3, respectively. These values are indeed in the expected ranges based
on the BG measurements of these patients. In addition, as we will describe later in more detail, the
estimated parameters are able to usefully predict the glycemic mean and variance of patients with
T2DM on time-scales of around three weeks. The forecast of glycemic mean and variance in response
to nutrition is limited to three weeks because the data shows non-stationary effects over longer time-
intervals. Figure 6.1 reveals parameter changes that, over four weeks, are significant enough to render
predictions less reliable, whilst on a three-week time horizon they are accurate.
To show that the UQ intervals are potentially useful in practice, once again consider Figure 6.1.
The range of UQ intervals for each estimated parameter in most of the cases contains physiologically
plausible parameter values that are tight enough to enforce the reliability of the point estimates
of the parameters. To quantify this statement we computed the coefficient of variation, defined as
the standard deviation over the mean. This measure is generally interpreted as a dispersion of the
probability density and can be interpreted as the variability of the distribution in relation to the mean.
Smaller values of coefficient of variation imply less variability or dispersion within the population and
that the distribution is accumulated around the mean. When the coefficient of variability is low, point
estimates of the mean are particularly meaningful and represent the population well whereas when the
coefficient of variation is large, the mean is less representative of the population as a whole. Note that
the population we are quantifying here is not of different patients, but rather a population of different
forecasts, parameter estimates, or realizations of the stochastic model, for the same patient at a given
time. For basal glucose rate, Gb, and amplitude of oscillations, σ, the coefficient of variation is in the
∼ 2− 3% band and ∼ 8− 20% band, respectively for all three patients, implying that the mean of the
estimated Gb is a very good point estimator. Even though the coefficient of variation values are not
as small for σ, these values are still quite small and demonstrate limited dispersion. Together these
results support the reliability of the point estimates that are used to form patient-specific models to
describe dynamics of each patient. In addition, the evolution of these UQ intervals for each parameter
over four weeks, present in Figure 6.1, demonstrates their sensitivity to time and the model’s ability
to adapt and capture the non-stationarity in the dynamics of patients over time.
We can see the robustness of the estimated parameter values by comparing parameter estimates
using two different methods, MCMC and optimization. The results are shown in Figure 6.1; the left
and right columns show parameter estimates using optimization and MCMC, respectively. The point
estimates as well as the corresponding UQ intervals for basal glucose value, Gb, and amplitude of
oscillations, σ, obtained with optimization and MCMC are very close to each other. Some parameters
have more variation between methods; specifically, the rate of decay to the basal glucose rate, γ,
and the meal function nutrition absorption parameters a and b do show variation between the results
obtained with optimization and MCMC methods. This variation does not seem to have substantial
effect on the model’s ability to represent patient dynamics. The overall result is a model whose ability
to represent the data is relatively insensitive to parameter estimation techniques.
6.1.2 Forecasting
The stochastic modeling approach is simple in the sense that we have few state and parameters and
the model’s high-frequency dynamics are represented as a diffusion process whose centroid is governed
by processes such as physiology-driven mean reversion. In contrast, this modeling approach is complex
because a stochastic process doesn’t have an explicit glucose trajectory—a particular glucose value—at
a given time but rather is a function that defines a glycemic distribution at every time point, e.g., with
a mean and a variance. Because of this subtly, the model is both intuitive—it reflects what we know
and do not know about glycemic dynamics at given, unmeasured, time—and it is foreign because there
is not an explicit glycemic trajectory. However, we can construct an example glycemic trajectory, or a
realization of the stochastic process by sampling the SDE-defined glycemic distribution at every time
point. In another words, the realization is one of the infinitely many possible trajectories that the
stochastic process could follow when it is realized. Similarly, we assume the collected measurements
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represent a realization of a random process that is described by the solution of our SDE model.
Together these pieces form a framework within which we interpret and evaluate the model. As such,
we evaluate the model along two pathways, a face validity pathway that is mostly motivated by
potential clinical decision-making, and a more statistical-based pathway that is motivated by our
desire to be quantitative. In a sense, both evaluations address whether the data could plausibly be
generated by the model.
The first evaluation—face validity—is to consider whether the model can capture the dynamics
qualitatively. Because the model’s forecast is in the form of a distribution, the forecast we have to
evaluate is anchored to the mean and standard deviation. An initial inspection of Figure 6.2a where
the red circles represent the true BG measurements and blue crosses represent one realization of the
model over only the first week of the test set does indeed seem to represent the data well.
The second evaluation quantifies how plausible it is that the data we observe could have originated
from the model. We quantify this plausibility using the two-sample Kolmogorov-Smirnov (KS) test.
To start, Figure 6.2b shows the kernel density estimates obtained from the BG measurements (blue
curve) and from ensemble of 100 different realizations of the estimated stochastic process (red curve)
over the same time period in Figure 6.2a. To generate the data to compute the model-based density
estimate we select a sample from the distribution defined by the model at every time point. The model
can also be visualized as a probability density function; for example, the kernel density estimate of a
model realization is the probability density function of the distribution and the real data are shown in
the right panel of Figure 6.2. The similarity of the behavior of the estimated realization (blue crosses)
with the assumed realization (red circles) of the stochastic process in Figure 6.2a and kernel density
estimates in Figure 6.2b support the idea that both are plausible draws from the same distribution.
To calculate the two-sample Kolmogorov-Smirnov (KS) test we created data sets: (i) resampled 1,000
points from the raw BG measurement data, and (ii) a realization of the estimated stochastic process
over the same time period as shown in Figure 6.2a. The two-sample Kolmogorov-Smirnov test did
not reject the hypothesis that the two samples came from the same distribution with a p-value of
9.8217 ∗ 10−9. This implies that our initial assumption, which is that the BG values can be described
by our simplified stochastic model, is indeed a valid assumption in this setting.
Given this understanding of the model, our evaluation of BG forecasting focuses on evaluating
(a) An arbitrary realization with BG measurements (b) Kernel density estimates
Figure 6.2: In (6.2a) a realization of the estimated Ornstein-Uhlenbeck process is shown over the first
week of the test data along with the true BG measurements, and in (6.2b) kernel density estimates
of BG measurements and realizations of the estimated model are shown. In 6.2a, the red circles show
true BG measurements, the blue crosses show an arbitrary realization of the model output, and the
gray area represents the estimated 2-stdev band around the mean of the model output. This figure
shows rationale behind the MSG model. Comparison of the true BG measurements and an arbitrary
realization of the estimated distribution implies that they could indeed be considered as two different
realizations of the same random process, as most of the true and simulated BG levels stay within the
2-stdev band.
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(a) Patient 1
(b) Patient 2
(c) Patient 3
Figure 6.3: Forecasting results in the T2DM setting obtained via models formed by using the esti-
mated parameters with the optimization approach. In each plot, the red circles show the true BG
measurements, the blue curve shows the mean of the model output, and the gray region is the esti-
mated 2-stdev band around the mean of the model output. These forecasting results show that the
proposed model mean, when equipped with confidence bands found from standard deviations, esti-
mate the BG levels accurately, and in a patient specific way. This reinforces the claim that the model
parameters could be used to provide information about the health condition of individual patients.
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the ability of the model to estimate and track the mean and variance of BG levels. The MSG
model’s forecast is in the form of a distribution because it is stochastic and is therefore represents
the glycemic distribution at every time point. In this way, the only forecast we have to evaluate is
the mean and variance. And, clinical understanding and decision-making is done relative to the mean
and variance of glycemic dynamics. As such we have two key results. First, the forecasted mean of
the MSG model output, the stochastic model for BG movements, captures the essence of the behavior
of true BG measurements in a realistic way. And second, the forecast uncertainty as quantified using
the standard deviation of the process encapsulates a large percent—94% on average over the three
patients—of true future BG measurements while remaining narrow enough to delineate changes in
nutrition input and potentially treatment strategy. Surprisingly, the forecast uncertainty is more
narrow than the empirical uncertainty while capturing more of the data, meaning that the forecast
uncertainty captures the future uncertainty of the data more accurately—more narrow but more
specific—than the data themselves capture their own uncertainty. This is of course possible because
the model is modeling glycemic response, not just the glycemic time-series. Because the optimization
and MCMC approaches produced very similar parameter estimation and hence forecasting results, we
only used the MAP estimators obtained with the first week of data to form the patient-specific model
for forecasting over the following three weeks.
The mean of our glucose model represents the mean glycemic homeostasis and the mean glycemic
response to nutrition. Figure 6.3 demonstrates how this mean reflects the dynamics of true BG
measurements. In this figure we estimated the model parameters using one week of data, producing
a model of the glycemic homeostasis and response given nutrition input. To evaluate the forecasting
ability of this model we then use this model to forecast glucose for the following three weeks. The
subfigures of Figure 6.3 show the resulting forecast of BG for patients 1, 2, and 3, respectively for
the three weeks after the model was estimated. In each subfigure, red circles represent the BG
measurements, the blue curve shows the mean of the MSG model output and the gray area is the
2-stdev band around the mean. We see that the blue curve—the proper forecast—encapsulates the
behavior of the true measurements for each three patients.
Not all glycemic responses follow the mean, and forecasts carry uncertainty. One particularly
important and challenging task of a forecast is accurate estimate of uncertainty. Because of the
nature of our stochastic model, uncertainty is quantified naturally using the standard deviation of
the model process. Figure 6.3 demonstrate the effectiveness of the models’ ability to capture relevant
forecast uncertainty with two standard deviation (2-stdev) bands around the model mean; these bands
capture nearly every future BG measurement. These results are further quantified in Table 6.1 that
shows summary statistics for how often the measurements were captured by the 2-stdev bands as
well as the estimated standard deviation of BG measurements and the empirical standard deviation
obtained directly from the raw BG measurement data. Being able to contain ∼ 90−97% of the true BG
measurements in these confidence regions with a smaller model standard deviation than the empirical
standard deviation for all three patients is an indicator of this model’s capability in capturing the
patient dynamics and hence its predictive capability. This model is providing substantial forecasting
information beyond what is available given the data alone.
1-stdev % 2-stdev % model stdev data stdev
Patient 1 73.66 94.20 19.3700 24.4629
Patient 2 62.66 89.87 25.6625 32.5589
Patient 3 51.61 96.77 22.2388 27.1433
Table 6.1: Percentages of the true BG measurements included in the forecasted 1- and 2-stdev bands,
in the T2DM setting. Besides visuals provided for forecasting results, this table shows indeed a large
amount of true BG measurements are captured in the forecasted confidence intervals. Comparison of
the model stdev with the raw BG data stdev shows that the confidence intervals act really as tight
bands around the measurement values, hence providing true information about their variance.
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6.1.3 Comparison of Forecasting Accuracy with LDP Model
In this section, we will compare the forecasting accuracy of the T2DM version of the MSG model with
a well-known model developed by Ha & Sherman [36]. It is important to note that this model, the
longitudinal diabetes pathogenesis (LDP) model, was designed to understand diabetes progression, not
for forecasting future BG level purposes. The experiment in this setting will be the same as described
above in Section 6.1.2. This model consists of a set of coupled ODEs. To estimate the unknown model
parameters within the LDP model we use a constrained ensemble Kalman filter (EnKF) algorithm,
whose details can be found in [2]. As a result of using this type of an algorithm, whose output
comprises an ensemble of estimates, we can also assess the uncertainty in the estimated parameters,
using the ensembles. Moreover, we can propagate the uncertainty in the estimated model parameters
to quantify the uncertainty in the forecasted model states. Thus, using this approach, we can obtain
confidence bands, as we do with the MSG model. The LDP model that we use for comparison has 11
model parameters. However, we will not attempt to estimate all these parameters as it is not a feasible
task to achive with the sparse data that we have available. Instead we set some model parameters
to reasonable values based on the literature, and estimate the remaining ones using the constrained
EnKF method. More precisely, we perform the same experiment by estimating three different sets of
parameters, {σ, SI}, {σ, SI, hepaSI}, {σ, SI, hepaSI, r20}, and setting the remaining parameters at
known default values. The comparison results can be found in Table 6.2.
The results in Table 6.2 show that the MSG model is better at forecasting future BG levels in
T2DM patients than all variants of the LDP model considered. First, even though we fit the normal
distributed model output to the data rather than directly fitting the mean of the model output to
the data, we can achieve smaller MSE and MPE than all different variations of the LDP model for
all three patients. Second, we see the advantage of using a stochastic model which quantifiies the
level of certainty in the BG predictions for both the LDP and MSG cases. It is worth noting that
the MSG model is based on learning parameters of a stochastic model, whilst the LDP quantifies
uncertainties by learning an ensemble of parameters; this may contribute to the differences between
them at the level of uncertainty prediction. The pecentages in Table 6.2 show that the MSG model is
substantially better in capturing the true measurements in the corresponding confidence bands. Note
also that the MSE is also smaller for the MSG than for the LDP, demonstrating that it is preferable
as a point estimator, as well as probabilistically. In summary the MSG model is preferable to the
LDP for decision making in the context we use here, as it gives a better point forecasts and better
confidence bands, enabling knowledge of possible high and low values for future BG levels.
Finally, we want to note also that the datasets belonging to Patient 1 and Patient 2 here were
also used in [6] to compare the efficacy of some other data assimilation techniques to forecast future
BG levels. Among different filtering approaches and mechanistic models, the best performance was
achieved by a modified dual unscented Kalman filter (UKF) that estimates both the states and
unknown model parameters that is used along with the Ultradian model. With this approach, the
MSE for patient 1 is reported to be 680 (mg/dl)2 whereas it is 950 (mg/dl)2 for patient 2. This shows
that we obtain better forecasting accuracy with the MSG model for patient 1, however, the forecasting
accuracy is better for patient 2 with the UKF approach used with the Ultradian model. In addition,
the authors used the well known Meal model, introduced in [21] for forecasting future BG levels. For
this model, among various different filtering techniques, they achieved the best accuracy again with
UKF. The MSEs obtained with the Meal model along with UKF are 730 (mg/dl)2 and 1300 (mg/dl)2
for patients 1 and 2, respectively. The MSG model achieves better forecasting accuracy than the Meal
model for both of the patients. These comparisons are another indicator that the MSG model can
provide accurate forecasting results for T2DM patients without including exogenous insulin as a state
variable and with a relatively simpler representation of the underlying physiology.
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6.2 ICU
We now move from evaluating the model with T2DM self-management data to the more complex and
difficult case of modeling and forecasting glycemic dynamics in the ICU, where non-stationarity is
manifest on much shorter time-scales. Parameter estimation and prediction are, in general, harder
in the ICU context because patients within the ICU typically have much more volatile physiological
dynamics for at least three reasons: glycemic dynamics under continuous feeding are oscillatory, the
patients are acutely ill and their health state changes quickly because of their disease state, and the
patients are constantly being intervened on to help them heal. To paint a picture, 90%+ of the
patients will not require insulin outside of the ICU but do during their ICU stay, and around 20% of
patients have a hypoglycemic episode that would not occur when they are not acutely ill. The ICU is
a much more complex forecasting and modeling setting.
6.2.1 Parameter Estimation
The difficulties presented in the ICU setting are reflected in our parameter estimation results. Despite
these complexities, Our numerical results exhibit four substantive pieces of evidence which support
the validity of the model and its potential effectiveness for both understanding the physiological state
of an individual, and for forecasting for that individual, in the context of ICU patients. First, the
model captures the dynamics as meaningfully as possible based on the data. That is, the estimated
model parameters are physiologically plausible and represent the observable dynamics. Second, the
estimated model parameters, which have the most influence in resolving the mean and variance of the
BG level, are physiologically meaningful in most of the cases, as was the case in the T2DM setting.
Third, the changes in the parameter estimation results over moving time windows are realistic and
reflective of the expected non-stationary behavior of ICU patients. And fourth, the UQ results show
that the parameters (basal glucose rate, Gb and the model standard deviation, σ), which have the most
Patient 1
1-std % 2-std % mse rmse mpe
MSG Model 73.66 94.20 403.94 20.10 12.84
LDP Model
σ, SI 41.96 65.62 524.03 22.89 13.72
σ, SI, hepaSI 40.18 66.96 483.99 22.00 13.77
σ, SI, hepaSI, r20 43.30 65.62 487.89 22.09 13.59
Patient 2
1-std % 2-std % mse rmse mpe
MSG Model 62.66 89.87 1123.40 33.52 17.35
LDP Model
σ, SI 20.89 37.34 1563.20 39.54 21.00
σ, SI, hepaSI 15.82 32.91 1952.30 44.18 24.20
σ, SI, hepaSI, r20 18.35 33.54 1630.60 40.38 21.71
Patient 3
1-std % 2-std % mse rmse mpe
MSG Model 51.61 96.77 586.32 24.21 17.11
LDP Model
σ, SI 29.03 50.00 1043.40 32.20 18.98
σ, SI, hepaSI 30.65 53.23 1080.90 32.88 18.69
σ, SI, hepaSI, r20 19.35 46.77 1117.60 33.43 19.81
Table 6.2: Comparison of the forecasting results with two different models. For each different case of
the LDP model the results in the corresponding row shows which parameters are estimated during the
whole forecasting experiment. Note that we obtain better forecasting accuracy with the MSG model
than with the LDP model. Furthermore, for the LDP model, the forecasting accuracy decreases as
the number of parameters being estimated increases.
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influence in resolving mean and variance of BG levels are estimated with more certainty. Having tighter
bands around the point estimates for these parameters indicates the robustness of the estimation.
(a) Gb=108.24, γ=0.09, σ=1.35 (b) Gb=135.23, γ=0.51, σ=0.0016 (c) Gb=139.87, γ=1.00, σ=10.17
Figure 6.4: BG simulations are shown with respective to the estimated parameters over training time
window. In each plot, the light blue curve is the glucose rate in the nutrition delivered to the patient
(right y-axis), the red circles show the true BG measurements (left y-axis), the red curve is the mean
of the model output (left y-axis), and the gray area is the 2-stdev band around the mean of the model
output (left y-axis). These figures show two main cases that could arise as a result of parameter
estimation in the ICU setting: Figure 6.4a: The input (nutrition rate) is reflected in the output
(BG measurements), Figures 6.4b and 6.4c: The input is not reflected in the output, which makes it
impossible to estimate the decay rate γ.
Before we begin the evaluation, first consider Figure 6.4, which demonstrates both the model’s
relative robustness and its capability of capturing the dynamics and various complexities encountered
in different conditions in the ICU setting. These figures show simulated BG values for patient 4 (see
Table 5.2) over different training time windows, whose data, nutrition rate and BG measurements,
are used to estimate the corresponding model parameters using the optimization approach. Here the
the red curves represent the mean of the blood glucose dynamics that are assumed to be oscillatory,
the amplitude of oscillations are expected to lie in the gray region as it is the 2-stdev band around
the mean, and the BG measurements are shown as red circles and the blue curve shows the tube-
nutrition input rate. For simplicity we are considering patient 4 who did not need external insulin,
so the tube-feed nutrition is the only driver of the BG level. Each subfigure of Figure 6.4 shows a
different training time window that is representative of different circumstances relative to our ability
to estimate the basal glucose rate Gb, the decay of glucose to the basal rate, γ, and the parameter
that resembles the width of the glycemic dynamics, σ. Figure 6.4a shows a situation where the BG
measurements reflect the nutrition rate quite well. In this case all the estimated model parameters are
physiologically meaningful and the resulting simulation is a good representative of the dynamics, as
can be seen by the parameter and state estimates tracking one another. In contrast, Figures 6.4b and
6.4c demonstrate a situation where the BG measurements do not reflect the nutrition rate over the
time window; this failure is seen by the lack of consistency in the movement of the parameters to one
another and the nutrition rate. This failure can have one of two sources. First, if there is no change
in the nutrition rate over the training time window, it is impossible to estimate the glycemic decay
rate parameter, γ. Second, when changes in the BG measurements are uncorrelated with the changes
in the nutrition rate, potentially due to changes in health states or other interventions, e.g., other
hormone drips, it is also impossible for the model parameters to accurately reflect the physiology as
they are accounting for dynamical glucose features they were not designed to accommodate. These
issues do not mean the model cannot represent and forecast the glycemic dynamics, it still is usually
able to represent glycemic dynamics, but some of the parameters might lose their intended meaning.
For example, in the two respective examples, despite parameter estimate issues, in both of these cases
the estimated basal glucose rate, Gb, and the the parameter, σ that is a measure for the amplitude of
the BG level oscillations are physiologically meaningful and these parameters are enough to capture
the mean and variance of the BG measurements accurately. Moreover, estimated decay parameter,
γ, takes an arbitrary value larger than a pre-set threshold resulting in that the mean of the model
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(a) patient 4
(b) patient 5
(c) patient 6
Figure 6.5: Parameter estimation and uncertainty quantification results in the ICU setting obtained
with MCMC approach. In each plot, the blue stars represent the point-estimate of each parameter
(mean of the resulting random samples) and the gray area is the 2-stdev band around the point-
estimates (also obtained from the resulting random samples). These results show that the estimated
model parameters exhibit biophysically realistic values and change relatively smoothly; this is to be
expected since the consecutive (moving) time windows (each of length around one day) have a large
overlap. However, the cases where there is a considerable change in the estimated parameter are also
understandable because of rapid changes in the patients’ health condition and/or the difficulty in
extracting such information due to patients’ glycemic response. On the other hand, 1- and 2-stdev
bands enforces the reliability of the estimated parameters, especially, Gb and σ, which are the most
important parameters in predicting the mean and variance of BG levels.
29
being estimated as flat. These examples are not the only cases where we observe parameter estimates
that are not physiologically meaningful while at the same time the glucose forecast and modeling
itself remains accurate. The other examples are all variations on the same theme; we do not have the
available data to estimate a parameter accurately, or the data are behaving in a more complex manner,
and in both cases, the parameters make up for these data-driven and model-driven short-comings by
deviating from their normal roles to render a robust glucose forecast. It is likely that problems such
as these will not be eliminated by using more complex data sets and more complex models, because
full representation of the relevant processes is out of reach in such non-stationary ICU settings.
With the complexity of ICU data in mind, Figures 6.5 and 6.6 show the time course of parameter
estimates for each ICU patient obtained with MCMC and optimization approaches respectively, and
demonstrate how the estimated parameters are physiologically plausible. In Figure 6.5 we show
estimated basal glucose rate, Gb, the decay parameter, γ, the parameter used as a measure for the
amplitude of BG level oscillations, σ, and the proportionality constant, β, for each of the patients.
The mean of each parameter, as estimated using MCMC, is shown using blue stars; the parameters are
estimated for every forecasting process using data from the previous day allow us to update the model
to forecast the glycemic response and states, implying a moving time window of parameter estimates.
These parameter estimates are physiologically plausible for all three patients except in a small number
of cases. For example, estimates of the basal glucose rate, Gb, were around ∼ 110 − 150mg/dl,
∼ 140− 200mg/dl, ∼ 120− 200mg/dl, for patients 4, 5, and 6, respectively, all plausible values given
the patient’s data. As was the case for the example discussed in the first paragraph of this section, it
was not possible to compute good estimates for parameters γ and β in some of the cases.
If we estimate the parameters using optimization—changing the paradigm under which we estimate
parameters—we can gain further insight into complexities regarding parameter estimation. Figure 6.6
demonstrates some variability and occasionally unrealistic estimates for basal glucose rate, Gb. In
Figure 6.6 we observe times where the basal glucose rate, Gb being estimated very low, too low to be
plausible. The reason why the basal rate is estimated incorrectly, however, is not so complex and is
in fact correctable. The time periods where the basal rate is incorrectly estimated coincide with time
intervals where we cannot estimate the decay rate, γ; this problem occurs again when the nutrition
rate is not changed over the course of the training period, making it impossible to estimate glycemic
response to nutrition. If, over the course of the optimization, the decay rate is estimated to be too high,
it negates the effect of nutrition to the BG rate. Because the model now has much less dependence
on nutritional input, it makes up for this by estimating the basal rate, Gb as being higher than it
should be. In contrast, if the estimated decay rate, γ, is underestimated then the influence of nutrition
on BG is excessive and, to make up for this, the basal rate is underestimated. In this situation we
can still calculate the basal rate accurately by estimating the shifted basal rate, which is the sum of
estimated basal glucose value and estimated effect of nutrition rate. This shifted basal rate is how the
model is modeling the glucose in the system, and the calculation for the shifted basal rate is effectively
deconvolving how the model is coping with the data insufficiency. This example demonstrates some of
the ICU-specific complexity and that, despite the identifiability failure due to data sparsity, the model
was robust enough able to estimate the data. And, because the model is relatively simple, this further
demonstrates how we are able to pull apart the modeling inaccuracies such that we can understand
and account or otherwise compensate for these model errors. In addition, the estimated σ values which
are the measures of the amplitude of BG level oscillations, attain physiologically meaningful values,
using the optimization approach, as well. This is important because it is generally the amplitude of
oscillations that will have the largest impact on clinical decision-making. And finally, despite these
difficulties, the BG dynamics were still quite accurate as we will see in the forecasting evaluation (cf
Figures 6.7 and 6.8).
Figure 6.5 also shows that the time evolution of the estimated parameters is realistic within the ICU
context. In ICU the training time windows move in positive (increasing time) direction increments
of measurements—given a measurement the model is estimated using the previous 24 hours of data,
∼ 14 data points to forecast the future measurement whenever it comes—so that the consecutive time
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(a) patient 4
(b) patient 5
(c) patient 6
Figure 6.6: Parameter estimation results in the ICU setting obtained with the optimization approach.
In each plot, the blue stars represent the MAP estimator of the corresponding model parameter.
These results provide important understanding of the system through the cases whether the data is
interpretable through the model or not. When both of the basal glucose value, Gb and the decay
rate, γ attain physiologically plausible values, this is mostly representative of a case where the data
is interpretable through the model, whereas other cases reflect when it is not possible to estimate the
decay rate and how this situation propagates through the other estimated parameters.
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windows have an overlap of 20-23 hours. This means that the model varies relatively continuously
between consecutive time windows. This relative continuity is reflected in Figure 6.5 that shows the
time evolution of estimated parameters for all three patients. The choice of the time window used to
estimate the model faces the same problem that all moving window approaches: short time windows
imply less data and higher estimation variance and long time windows imply poor adaptability in
non-stationary settings but have lower variance and ample data. This is an optimization problem we
will not tackle here. Instead, we set the window size on the assumption that the patient health state
defined by the parameters would not change too much over the previous 24 hours, and assumption
that is usually but not always correct. Even though the health condition of the ICU patients can
change rapidly, the estimated parameters do not change wildly (in most of the cases), reflecting
the expectation under these settings. Nevertheless, the patients are clearly non-stationary and the
observed evolution of the parameter estimates, e.g., of the basal glucose value, Gband decay rate, γ,
shown in Figure 6.4 reflect this non-stationarity.
And finally, as was the case in the T2DM setting, the model is relatively robust to the methods
used to estimate it; however, as can be seen in Figure 6.8 and inferred from the discussion above
about parameters and their face validity to physiology, the ICU formulation of the model can have
more complex parameter estimation issues compared to the T2DM setting. In particular, in the
ICU setting there are some cases where the Laplace approximation does not work well because the
parameter misfit solution surface is flat in some parameter directions – a reflection of identifiability
issues. In these cases we used MCMC to provide UQ results. In general we observe that the basal
glucose rate Gb and the parameter related to variance, σ, both allow for more robust estimation
compared to the estimation of γ and β. The robustness of the estimation of σ is important for clinical
applications because the variance, σ, is what is used for deciding insulin doses. As a demonstration
of the robustness of σ, consider Figure 6.5. Here we can see the 2-stdev band around the mean for σ
is tighter than or as tight as the 2-stdev bands for Gb, γ, and β for all three patients. This implies
that the MSG model is able to robustly estimate the amplitude of the BG level fluctuations, which
again is important to clinicians. On the other hand, considering the plots for γ and β estimation, the
width of the 2-stdev bands shows that we are less certain about the estimated values. Remember that
both of these parameters are related to the glucose removal rate from the blood. This is, perhaps,
an indicator of an identifiability issue for these parameters. But it is also true that we are indeed
less certain about this physiology; glucose can be removed at different rates by different physiological
processes, e.g., liver versus adipose tissue, and we are not resolving these physiological subsystems.
Moreover, due to the non-stationary and sparse nature of the data in the ICU setting, it is harder to
estimate some of the model parameters accurately. Separating these inference issues is not possible
given the data presently collected in these settings. Nevertheless, the parameters that play a key role
in resolving the mean and variance of the BG dynamics can be estimated accurately up to the desired
level.
6.2.2 Forecasting
Forecasting results in the ICU setting are indicative of two major features of this model: (i) we can
capture the trend of BG measurements through the mean of the model and (ii) we can estimate the
variance of the BG measurements accurately. Once again, since resolving mean and variance of BG
dynamics is central to glycemic management, these results show potential usefulness of this model in
the ICU context.
Figures 6.7 and 6.8 demonstrate that the forecasted mean of the model and reflect it encapsulates
the essence of the behavior of BG measurements for all three patients. In each of the plots in Figures
6.7 and 6.8, the red circles show the BG measurements and the blue stars are the mean of the model,
the gray region is the 2-stdev band around the mean once again obtained separately for each forecasting
process with the corresponding patient-specific model. In addition to representing the trend of the
BG measurements, the forecasted mean of the model is nearly identical when computed using two
independent methods, reinforcing the point that the model is reliable.
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(a) patient 4
(b) patient 5
(c) patient 6
Figure 6.7: Forecasting results obtained based on parameters estimated with optimization, in the ICU
setting. In each plot, the red circles show the true BG measurements, the blue stars show the mean
of the model output, and the gray region shows the 2-stdev band around this mean. For all three
patients, the forecasted mean captures the actual behavior of BG levels (not used in the training of
parameters). Moreover, the 2-stdev band narrows down over the time periods on which BG levels
are relatively stable, and widen over the intervals where the BG value has larger variance. Capturing
this behavior with reasonably tightly confidence bands is a very useful and valuable feature of the
proposed model.
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(a) patient 4
(b) patient 5
(c) patient 6
Figure 6.8: Forecasting results obtained based on parameters estimated with MCMC, in the ICU
setting. In each plot, the red circles show the true BG measurements, the blue stars show the mean of
the model output, and the gray region shows the 2-stdev band around this mean. These results are, in
general, very close to those obtained using the optimization approach, and the most relevant properties
are shared by them both. Obtaining similar results with another numerical solution technique based
on the same mechanistic model shows the reliability of the model and estimated model parameters.
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1-stdev % 2-stdev % average model stdev
data stdev
optimization mcmc optimization mcmc optimization mcmc
Patient 4 59.06 64.33 94.15 93.57 16.69 17.48 17.21
Patient 5 60.62 67.36 84.46 87.05 25.70 29.09 29.15
Patient 6 55.81 62.40 86.05 89.54 33.64 37.79 38.12
Table 6.3: Percentages of the true BG measurements included in the forecasted 1- and 2-stdev bands,
in the ICU setting. These percentages show that a large number of forecasted confidence intervals
include the true BG measurements. MCMC approach provides slightly better rates, which is in
accordance with the higher average model stdev in the MCMC case. The average model stdev values
obtained with optimization and MCMC for all three patients are smaller than the raw data stdev in
all but one case. Together with the percentage values, this means that the confidence bands are tight
enough to provide accurate information on the variance of BG levels in the ICU context, as well.
To observe the effectiveness of this model in estimating the variance of the BG measurements
accurately, consider Figures 6.7 and 6.8 and Table 6.3. Figures 6.7 and 6.8 shows the ability of the
models to estimate the variance in glycemic dynamics visually where a large number of true BG
measurements are contained in the gray regions that represent the forecasted 2-stdev bands around
the forecasted mean. These results are quantified in Table 6.3 which contains summary statistics both
for optimization and MCMC methods. We see that with one exception, MCMC model estimation for
patient 4, the average model standard deviation is smaller than the empirical standard deviation of the
BG measurements, yet the proportion of the BG measurements captured in these regions are in the
range of 84 − 94% for all three patients with two different methods. These results demonstrate the
forecasting accuracy of the MSG model, and imply potential use in the ICU for glycemic management.
6.2.3 Comparison of Forecasting Accuracy With The ICU Minimal Model
In this section, we will use the ICU Minimal Model (ICU-MM) introduced in [82] and [39] for the
comparison of the forecasting result we obtain with the ICU version of the MSG model. The ICU-
MM has twelve unknown model parameters. One of those model parameters is used for the purpose
of having units equal on both sides of the equation and set to be 1. Two of the model parameters
represent the volume of glucose and insulin distribution space and are set to nominal values from the
literature. This leaves us with nine unknown model parameters to be estimated. To estimate these
parameters, we use the constrained EnKF method as we did in when fitting the LDP model in the
T2DM setting. Recall that with this type of approach, the ensemble enables us to obtain confidence
bands for our forecasting results.
The numerical results for the comparison are shown in Table 6.4. First, similar to the results in
T2DM setting, the percentages of the true BG measurements that are captured in the 2-stdev bands
with the MSG model are higher than the ones obtained for the ICU-MM by using the constrained
EnKF algorithm. Second, the point estimators in the MSG case exhibit comparable, or improved,
accuracy in comparison to the ICU-MM: MSE and MPE are also smaller for the MSG model except
for patient 4. These results show that with a relatively simple model, we are able to reach the
same, or better, accuracy in forecasting BG behavior than a more physiologically based high-fidelity
model, with a larger number of unknown model parameters. Third, the confidence bands that we
use to quantify possible high and low values of BG level could provide better results. The improved
accuracy of the MSG model in terms of uncerainty forecasting may be related, in part, to the fact that
the model we use is inherently stochastic, and fits the stochastic fluctuations to data; in contrast in
the ICU-MM provides uncertainty bands only through the ensemble of solutions which are a product
of the algorithm used to fit the data, and not inherent to the model itself. Once again, this improved
forecast and uncertainty accuracy is indeed a crucial tool in making decisions regarding future BG
levels of ICU patients.
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patient 4
1-std % 2-std % mse rmse mpe
MSG Model 60.23 93.57 343.31 18.53 11.03
ICU-MM 49.71 80.70 335.15 18.31 10.48
patient 5
1-std % 2-std % mse rmse mpe
MSG Model 60.62 84.46 1104.20 33.23 19.20
ICU-MM 23.83 49.22 1480.40 38.48 20.52
patient 6
1-std % 2-std % mse rmse mpe
MSG Model 55.81 86.05 1927.50 43.90 25.84
ICU-MM 26.74 46.90 2018.40 44.93 25.28
Table 6.4: Comparison of the forecasting results obtained with the MSG model and the ICU-MM. The
percentages of 1- and 2-stdev bands that capture the true BG measurements with the MSG model is
substantially higher than the ICU-MM. On the other hand, MSE and MPE values are much closer
yet the MSG model still provides smaller value for these measures, as well.
7 Conclusion
Summary of the modeling framework: In this paper, we introduce a new mathematical model
that describes the glucose-insulin regulatory system in humans. The model was developed with five
goals in mind: (i) to create a model anchored to real clinical data, and that given these data the
model would be useful for personalized parameter estimation and state forecasting [73]; (ii) to create
a model that was interpretable in the sense that patient specific parameters may be used to explain,
and quantify, basic physiological mechanisms; (iii) a model which is physiologically simple, even
if it was functionally complex, to avoid parameter identifiability problems present in many existing
physiological models; (iv) a model framework generalizable and adaptable to several contexts including
T2DM and glycemic management in the ICU; and (v) a model that was amenable to a model-based
control environment.
With these goals driving the model development, the model we developed follows a somewhat dif-
ferent approach compared to many other glucose-insulin modeling efforts where the goals of increasing
physiological fidelity, or explaining a new physiological subsystem, were drivers. For example, where
as others, e.g., Sturis et al. [77] or Lui et al. [55], work to understand and resolve the nature of the fast
time-scale oscillations, the model developed here incorporates these sub-day glucose fluctuations into
the noise process and the parameter estimation is aimed at capturing the slower moving dynamical
properties such as the evolution of the rates of glucose use and production; this is done whilst keeping
their compartmentalization, and thus number of parameters, to a minimum. We do this because in
many cases we do not have data to support resolution of higher-fidelity physiological processes [43]
as is the case in many common real-world data collection settings. And, since our overarching goal
and model validation and evaluation metrics are based on the models’ ability to forecast future BG
levels accurately, for the sake of computational efficiency, we end up developing a lower-fidelity model
which is simple yet interpretable and anchored to physiology.
Summary of key results: The model developed here is flexible enough to enable a priori plausible
models valid for T2DM and ICU settings. Experiments with T2DM and ICU data demonstrate
that this a priori plausibility is borne out a posteriori. The model has physiologically interpretable
parameters, which can be estimated robustly based on real-world data. Moreover, the estimated
parameter values are physiologically plausible for both the T2DM and ICU settings. Hence, the
new model has demonstrable capability to capture the BG dynamics of T2DM and ICU patients;
in particular it does so well enough to resolve the mean and variance of their BG levels in both
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retrospective and predictive modes. This feature of the model reveals its potential for use in glycemic
management. It also reveals the potential for future BG level forecasting. After being trained based
on one week of data, it can accurately forecast future BG levels for the following three weeks in the
T2DM context. On the other hand, in the ICU context, it is capable of capturing the dynamics based
on one day of data. Then, it can be used for forecasting BG levels for the following 2-4 hours. In
both settings, the choice of mathematical model naturally provides confidence bands for the future
forecasting of BG levels. These confidence bands are extremely helpful to have an understanding
about how low and how high BG levels could be in the future, and hence for the design of glucose or
insulin uptake strategies to ameliorate undesirable health effects.
Model development constrained by real world data: Restricting model development to the
constraints imposed by readily available real world data is a severe, but important, restriction. We
can hypothesize how physiology might work in detail, and we can envisage experiments to gather
new datasets that could exist to test our hypotheses; but we have not yet exploited data that are
readily available to forge an understanding of what can be explained and predicted given current data
acquisition instruments, cost constraints on data acquisition and time-constraints required for real-
time prediction. To help facilitate the circular process of allowing our knowledge of systems physiology
to inform and impact how people and clinicians manage the health of people, and help allow the gaps
in understanding at the bedside to help us choose impactful systems physiological problems to
focus our efforts on, we need a bridge between these worlds, and the bridge proposed here is through
inference with data based on simple yet interpretable models.
Application in clinical settings: Within a clinical setting there are two scenarios where model-
based efforts could be of potential help: (i) obtaining deeper understanding of the patient-specific
attributes of the glucose-insulin regulatory system; this requires accurate parameter estimation; (ii)
guidance for immediate decision-making such as insulin administration and glycemic management;
this is a situation where we can tolerate some inaccuracy with parameter estimation provided that
the state forecasts, including the uncertainty bands, are accurate and robust. In the context of the
model introduced here we have shown situations where the model parameter estimates are accurate as
well as situations where model parameter estimates are not accurate. Nevertheless, in the situations
where the parameter estimates are not accurate, the state forecast accuracy remains robust, and the
parameter estimate failures can be explained and for a large part mitigated. For example, in some
circumstances in the ICU we cannot directly estimate the basal glucose rate accurately, but we are
nevertheless able to obtain an accurate estimate of the rate at which glucose returns to its base value.
In many situations we demonstrate that this is enough to make accurate short-term forecasts; and also
provides a starting point for more fundamental physiologically-based systems. A key requirement when
translating the model framework to a clinical setting is quantification of uncertainty in predictions.
In this context our modeling effort was a success in both T2DM and ICU settings.
Blood glucose forecasting summary: The MSG model works well at estimating and forecasting
blood glucose mean and variation boundaries in T2DM and ICU settings. For example, the model-
based forecasts have more forecasting accuracy while retaining tighter uncertainty bands compared to
measures derived from the data alone. The model identifies different characteristic behaviors between
T2DM and ICU patients, demonstrating both generalizability and robustness of the models with
respect to forecasting. Moreover, in these two scenarios the models are able to cope with the relative
pace of non-stationarity of the patients, order weeks and order days for the T2DM and ICU settings,
respectively. This demonstrates both the efficiency of the MSG model and its flexibility. Given these
results and the fact that the model is simple and interpretable with understandable parameters implies
a potential for providing a new perspective in understanding the glucose-insulin system in humans.
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Comparison of the efficacy of the model for T2DM and ICU settings: The T2DM and ICU
contexts are very different settings, primarily because of the time-scales on which parameters change,
and the different relative importance of external events not included in the model; this difference
imposes different needs in the two settings. For example, the change of the health states of the
T2DM patients are in the order of days, or even weeks, whereas health states change on the order of
hours for ICU patients. Keeping these case-specific differences in mind, one obvious way to compare
the effectiveness of the model in these two settings is through the forecasting results. However,
unlike other fields such as atmospheric physics, biomedicine is mostly missing a standardized and
normalized techniques for context-sensitive forecast verification and evaluation, especially in regard
to clinical effectiveness of the forecast. Because of this gap, evaluation of the models and quantitative
comparison of their potential usefulness in a context-dependent way is not possible. Regardless, it
is important to emphasize that we do not expect the results for the two settings to have the same
accuracy due to the characteristic differences mentioned before. More precisely, comparison of Figures
6.3, 6.7, and 6.8 shows that the mean of the model output in ICU setting does not look as close to
the true BG measurements as the same comparative forecasts in the T2DM case. Once again, this
situation is expected due to highly non-stationary behavior of ICU patients. However, in this setting,
it could be argued that being able to forecast the variance of glycemic dynamics to identify, e.g.,
hypoglycemia, could be more important to capture than the dynamics with the mean model output.
These different needs are context-specific, and without context-specific evaluation machinery, direct,
quantitative comparisons are not yet possible. Instead we are left showing Figures 6.7c and 6.8c that
demonstrate the model can forecast a hypoglycemia event on day ∼ 13 for patient 6, a feature that
does demonstrate the context-specific effectiveness of the model in the ICU setting.
Developing a model that is as simple as possible but not simpler: While building the final
model presented here, we started with the simplest possible representation of each process and built in
complexity until the model had desired predictive capability. For example, to model the meal function
in the T2DM setting, we first used an impulse function that concentrates all the ingested glucose at
a single meal time instant. Numerical simulations showed that this choice was too simple to reflect
reality. The source of the problem is insightful: concentrating all of the glucose in the meal at one
time point, the start time of the meal, caused the corresponding simulated BG levels to increase very
rapidly to very high values, which were not even on the same order as the true BG measurements,
e.g., when BG measurements are in the range of ∼ 100 − 150 mg/dl, the simulated BG values are
in the range of ∼ 700 − 800 mg/dl. Physiologically, it is likely that a sharp spike in glucose intake
would cause a spike in BG, but it is also likely the spike would be narrow and BG would return
to near normal values quickly; however a full discussion of the physiological effects of such a dose
of glucose is beyond the scope of this discussion. We then tried a simplistic solution in which we
represented nutrition ingestion as a square-wave function, which was sum of constant functions that
have the value Gi/T over the interval [t
(m)
i , t
(m)
i +T ] where Gi is the total amount of glucose ingestion
in the meal starting at time t
(m)
i , and T is a time-scale for transfer of glucose from stomach to blood.
That is, we set m(t) =
∑Km
i=1
Gi
T χ[t(m)i ,t
(m)
i +T ]
(t), and let T be a model parameter to be estimated
for each patient from data. This function produced reasonable, realistic simulation results. However,
the cost function we minimize to fit the model to data (see (4.11)) exhibited discontinuities related
to discontinuous behaviour of the meal model with respect to T . The somewhat surprising result of
this discontinuity was our inability to accurately estimate glycemic responses to nutrition. Meaning,
with a square wave nutrition delivery function, inference failed. These failures led us to choose a
smooth function for nutrition delivery that then led to a continuous cost function with respect to the
unknown model parameters. These issues led to the meal function as defined in (3.1) that satisfies
both the requirements. Meaning, the model development was driven both by the need to reconcile the
model with realistic physiology and by the need to be able to preform inference with data. Similar
considerations applied to other aspects of model development.
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Impact of the Nutrition Function Choice in the ICU Context: We also consider different
form for the nutrition function in the ICU setting, in order to test robustness of our modeling to the
simplistic piecewise constant model that we adopt in this case, and in view of the fact that in the T2D
setting we found the need for a more sophistictaed model for nutrition uptake. First, note that because
of ICU patients are tube-fed with nutrition quantities that are considerably less, per unit time, than
a healthy indivudual would ingest, per unit time, over the duration of a regular meal, it is reasonable
to consider the use of a piecewise constant function to model the effect of nutrition on the BG levels
for ICU patients. Nonetheless we investigated if modifying the piecewise constant function as shown
in Figure 7.1 could improve the parameter estimation and/or forecasting results. The idea behind
this modification is to model the effect of nutrition on BG level via an initial exponential increase
that reaches a maximum value and then, when the nutrition delivery stops, this effect decreases
exponentially. The rate of increase and decrease are represented by two model parameters a and
b. These parameters are similar to the ones that we used to model the effect of nutrition in the
T2DM context, but the nutrition function is not exactly the same since the nutrition effect in these
two cases have different characteristics. In addition, since the values of these two parameters can
be patient-specific, using this function introduces two more parameters to be estimated in the ICU
setting, increasing the flexibility and the complexity at the same time. Hence the parameters to be
estimated are Gb, γ, σ, β, a, b.
Figure 7.1: Smoothing piecewise constant nutrition function that is used for ICU patients
The function we use has the following form:
m(t) =
Km∑
k=1
ck((1− e−a(t−t
(m)
k ))χ
[t
(m)
k ,t
(m)
k+1)
(t)
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(m)
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k ))χ
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(7.1)
where h
(m)
k := t
(m+1)
k − t
(m)
k and
ck :=
dkh
(m)
k
h
(m)
k + (e
−ah(m)k /a) + (1− e−ah
(m)
k )((2ln(2)− 1)/b)
,
is the normalizing constant for k = 1, 2, ...,Km.
The numerical results concerning the forecasting capability of the MSG model with this nutrition
function are summarized in Table 7.1. A quick comparison of these results with the ones in Tables 6.3
and 6.4 shows that the percentages for 1- and 2-stdev bands are a little less whereas MSE and MPE are
either the same or slightly higher than the ones obtained with piecewise constant nutrition function.
Hence this comparison suggests that using the more physiologically accurate version of the meal
function did not, in this ICU case, introduce any improvements. Since the new function introduced
two more new parameters to be estimated this also leads to a problem that is computationally more
39
challanging, especially when the problem is prone to identification issues. Overall our work comparing
the original and new meal function demonstrates that the original piecewise constant choice of the
meal function is an appropriate choice in this case.
1-std % 2-std % mse rmse mpe average model std
Patinet 4 56.73 91.81 392.90 19.82 11.87 16.86
Patient 5 59.59 83.42 1239.70 35.21 19.68 25.25
Patient 6 57.36 84.11 2094.70 45.77 26.01 33.40
Table 7.1: Forecasting results obtained with optimization approach for the MSG model with the
nutrition function given in (7.1). Even though the nutrition function could be considered as a better
representation of the reality, it did not introduce improvement in the forecasting results.
Comparison of Forecasting Efficiency with Other Models: In order to evaluate the effective-
ness of the MSG model, we ran experiments comparing it with the LDP model (the T2DM setting)
and with the ICU-MM (the ICU setting). The LDP and ICU-MM models are built to represent the
co-evolution of glucose and insulin dynamics, in contrast to our simplified model which models glu-
cose dynamics with insulin as parameterically-dependent input. For the purpose of comparison, we
used 1− and 2−stdev band percentages, MSE, RMSE, and MPE as the evaluation metrics. In both
the T2DM ICU settings we showed that: (i) even though the MSG model was developed to capture
the mean behavior of BG level, and the numerical scheme used for identification is not specifically
designed to minimize the MSE, the MSE over the test data obtained with the MSG level is typically
smaller than, and in the worst case at the same level as, the MSE obtained with the LDP model (for
T2DM) and ICU-MM (for ICU); (ii) the confidence bands obtained via the MSG model are more
effective in that they capture a higher proportion of the true BG measurements than the confidence
bands found from the LDP model and the ICU-MM. This is likely due in part to the fact that the
MSG model uses a stochastic description to encapsulate possible fluctuations around the mean in the
quanity of interest, which is the BG measurements; the LDP and ICU-MM are deterministic models
and fluctuations are captured through the ensemble method used to fit the data. These two points
show that the MSG model is at least as effective in forecasting future BG levels as the LDP and
ICU-MM models, in the T2DM and ICU settings; indeed it is typically more effective. Achieving this
level of accuracy in the two different settings is achieved by using a simple model, apprpropriate for
the available data, but complex enough to be interpretable and to capture the underlying physiology.
The resulting simple MSG model has a smaller number of unknown parameters than do the LDP and
ICU-MM models, therby providing more robust estimation and inference results.
Generalizability of parameter estimation: Finally, a careful investigation of the estimated pa-
rameters and simulated BG levels in the ICU context shows that we can estimate parameter values
that represent the BG levels very well when the true BG measurements are interpretable with the
model (3.8). That is, if measured BG values are responsive to the changes in the rate of nutrition and
insulin IV, then the BG simulations with the estimated parameters based on this data provide a very
good representation of the dynamics. However, if the BG level behavior is not driven by the nutrition
and the insulin IV rates, i.e., if its response is driven by other factors such as stress-induced counter-
regulatory hormone levels, then the model-estimated mean is estimated to be almost-constant. This
mean estimate is still good as a representation of the average of BG measurements and the variance
of the measurements are still estimated accurately enough that the 2-stdev band around the mean
envelopes nearly every BG measurement. For all patients in all disease cases, independent of param-
eter estimation complexities, we obtain good estimates of the forecast mean and variance of the BG
levels we achieve with the model are likely accurate enough to be helpful in clinical settings.
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Outlook: The model we have developed has demonstrable predictive capability and discriminates
between datasets in a patient-specific manner. Yes it has some limitations, which give space for
future development, and also suggests some natural next-step applications. We outline a number of
possible future directions. Glycemic control: Given the MSG model construction, an obvious next
step is to formulate the work on the control problem where we determine estimates of the input ranges
of nutrition and insulin, necessary to keep the output, here BG, in a desired target range. This is
a similar approach to something like the artificial pancreas/beta-cell project, but the inputs would
include nutrition, the settings would include T2DM and ICU glycemic management, and the goal
would not be a closed loop but rather an open loop system. Parameter estimation short-comings
and advancement: In T2DM setting, the estimation results with optimization and MCMC approaches
for the parameters a and b used to define the rate of appearance and absorption of glucose produce
conflicting results. In the ICU setting, we observe some identifiability issues for the parameters
modeling glucose removal with body’s own effort and with insulin IV. We plan to address these
issues in future. Key questions are whether different parameter estimation techniques can resolve
the problems, or whether further data is required, and if so which data, and more fundamentally
whether the model used is appropriate for the data. A related issue is the possibility of using mixed
effects models [75, 83] in order to share common information in different patient data sets, whilst
also retaining the advantages of patient specific learning. Comparison with more complex models:
In order to have a better understanding about the effectiveness of this model to encapsulate BG
dynamics and resolve the mean and variance of BG levels, we plan to compare it with more complex
models, such as a second order linear SDE (which would allow for oscillatory dynamics but retain
the advantages of linearity and Gaussianity exploited here) and the Ultradian model [77] (which is a
widely- accepted physiogically based model). Such a comparison would happen within design similar
to what we used in this paper for both T2DM and ICU context. Furthermore in the situation where
control machinery has been added to the model, we can evaluate the various model’s effectiveness in
a control-based setting. Phenotyping: Because the parameters of the MSG model are interpretable
and track physiology reasonable well, we could potentially use the model parameter estimates for
phenotyping studies, [4, 5, 7]. Meaning, we could estimate parameter for individuals in a given health
state, establishing an inferred phenotype for the patient, and then relate this phenotype to other
external health features or cluster the patient phenotypes in an effort to find structure among the
inferred physiology. We have deemed efforts such as this high-fidelity phenotyping [43] and believe
that this model has the potential to be used to these ends. Exploiting model error to understand
physiology: It is known that BG levels are mainly driven by the carbohydrates, however, there are
also other factors that impact glucose levels. A partial list of particularly interesting features that
impact BG levels and are of practical interest include macro-nutrients other than carbohydrates,
exercise, sleep, and stress levels of patients. The presence of these features will induce systematic
forecasting errors allowing us to use machine learning to explore the statistical relationship between
these factors and BG levels. This would give us a systematic platform for potentially furthering the
understanding of the glucose-insulin system and result in more accurate parameter estimation and
forecasting. Further model generalization to include other glucose-data driven situations: We have
not investigated how the MSG model might work given oral glucose tolerance test (OGTT) data. The
OGTT is one of the standard settings for glucose-insulin model development and potential use; we
know of only one model that currently generalized to both OGTT and clinical data [35] and we would
like to add the MSG model to this list. T1DM: We have a initial version of the MSG model that
could be used within T1DM setting. It would be interest to test this version on T1DM data. Since
the time-scales of health progression here are more similar to those of T2DM than the ICU setting,
giving hope that the method might have similar predictive capability in this setting. Because of not
having access to such a T1DM dataset, we haven’t been able to work with this version in this paper.
We plan to pursue a number of the research directions outlined here in the immediate future.
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